US20190134167A1 - Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases - Google Patents
Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases Download PDFInfo
- Publication number
- US20190134167A1 US20190134167A1 US16/095,270 US201716095270A US2019134167A1 US 20190134167 A1 US20190134167 A1 US 20190134167A1 US 201716095270 A US201716095270 A US 201716095270A US 2019134167 A1 US2019134167 A1 US 2019134167A1
- Authority
- US
- United States
- Prior art keywords
- cyp40
- active fragment
- biologically active
- polypeptide
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010048028 Cyclophilin D Proteins 0.000 title claims abstract description 179
- 102100037827 Peptidyl-prolyl cis-trans isomerase D Human genes 0.000 title claims abstract description 171
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 35
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 230000009467 reduction Effects 0.000 title abstract description 4
- 231100000189 neurotoxic Toxicity 0.000 title abstract description 3
- 230000002887 neurotoxic effect Effects 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 89
- 239000012634 fragment Substances 0.000 claims abstract description 75
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 102000001049 Amyloid Human genes 0.000 claims abstract description 26
- 108010094108 Amyloid Proteins 0.000 claims abstract description 26
- 238000001727 in vivo Methods 0.000 claims abstract description 21
- 230000002776 aggregation Effects 0.000 claims abstract description 19
- 238000004220 aggregation Methods 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 119
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 116
- 229920001184 polypeptide Polymers 0.000 claims description 114
- 239000002157 polynucleotide Substances 0.000 claims description 92
- 108091033319 polynucleotide Proteins 0.000 claims description 92
- 102000040430 polynucleotide Human genes 0.000 claims description 92
- 230000014509 gene expression Effects 0.000 claims description 50
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims description 44
- 239000013543 active substance Substances 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 15
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 13
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 101710115937 Microtubule-associated protein tau Proteins 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 3
- 201000004066 Ganglioglioma Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 208000017004 dementia pugilistica Diseases 0.000 claims description 3
- 201000008361 ganglioneuroma Diseases 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 3
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 230000002739 subcortical effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- -1 methods Substances 0.000 abstract description 8
- 239000002552 dosage form Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 42
- 230000000694 effects Effects 0.000 description 39
- 108010026424 tau Proteins Proteins 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 30
- 150000001413 amino acids Chemical group 0.000 description 28
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 25
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- 239000003814 drug Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 16
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 108091005750 disaggregases Proteins 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 238000004627 transmission electron microscopy Methods 0.000 description 9
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000004498 neuroglial cell Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 102000004195 Isomerases Human genes 0.000 description 6
- 108090000769 Isomerases Proteins 0.000 description 6
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 235000013930 proline Nutrition 0.000 description 6
- 102200036626 rs104893877 Human genes 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 5
- 108090000317 Chymotrypsin Proteins 0.000 description 5
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960002376 chymotrypsin Drugs 0.000 description 5
- 238000002983 circular dichroism Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229960003530 donepezil Drugs 0.000 description 5
- 229960003980 galantamine Drugs 0.000 description 5
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229960004640 memantine Drugs 0.000 description 5
- 229910052759 nickel Inorganic materials 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 229960004136 rivastigmine Drugs 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 3
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 3
- 241001044073 Cypa Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 3
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 3
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 3
- 101000932178 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 description 3
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 101100061197 Mus musculus Cyp27b1 gene Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003941 amyloidogenesis Effects 0.000 description 3
- 230000003942 amyloidogenic effect Effects 0.000 description 3
- 229940039856 aricept Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940108366 exelon Drugs 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 102000057063 human MAPT Human genes 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940051845 razadyne Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108700004121 sarkosyl Proteins 0.000 description 3
- 229940016590 sarkosyl Drugs 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108010067247 tacrolimus binding protein 4 Proteins 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 102100027831 14-3-3 protein theta Human genes 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150093441 CYP40 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101100137375 Homo sapiens PPID gene Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical class OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-WJNSRDFLSA-N 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-WJNSRDFLSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- IPCUHQYGWOKSLR-UHFFFAOYSA-N 5-aminohexanoic acid Chemical compound CC(N)CCCC(O)=O IPCUHQYGWOKSLR-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 241000538571 Brachydeuterus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 101150051208 HSPH1 gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282824 Hippopotamidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
- 101001095231 Homo sapiens Peptidyl-prolyl cis-trans isomerase D Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037874 Intercellular adhesion molecule 4 Human genes 0.000 description 1
- 101710148793 Intercellular adhesion molecule 4 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100451677 Mus musculus Hspa4 gene Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241001635529 Orius Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000282798 Rhinocerotidae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000055252 human PPID Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 101150108030 ppiD gene Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 108700029190 zebrafish elavl3 Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/52—Isomerases (5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
Definitions
- Disaggregation is important because many diseases result from aberrant protein aggregation, particularly in the brain.
- Hsp104 and cpSRP43 possess disaggregation activity, but there are no known mammalian orthologues [1]. More recently, it was shown that the chaperone Hsp70 works in a multi-protein complex with ATP to promote disaggregation of various amyloidogenic substrates.
- yeast disaggregase Hsp104 utilized ATP hydrolysis to disaggregate a variety of human proteins in a yeast model (6,7).
- metazoan Hsp70/DnaJ/Hsp110 complex was found to work with ATP to disaggregate amyloid substrates in vitro (8).
- the dynamic and ubiquitous nature of aggregation and disaggregation in cells suggests that a more energy-efficient process might exist, one that does not require ATP.
- CyP40 The peptidyl-prolyl isomerase cyclophilin 40 (CyP40), encoded by the PPID gene, has been identified to be an ATP-independent human disaggregase. CyP40, independent of any co-factors, dissolved fibrillized aggregates of two disease-relevant amyloids: the microtubule associated protein tau and ⁇ -synuclein. Overexpression of CyP40 in the rTg4510 tau transgenic mouse brain was neuroprotective and decreased fibrillar and oligomeric tau species. The disaggregating activity of CyP40 appeared selective for those proteins possessing proline residues, and was dependent on the prolyl isomerase activity of the enzyme. This work shows that a low energy human disaggregase can independently and selectively protect neurons from proteotoxicity in the mammalian brain.
- the present invention concerns compositions and methods for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof.
- CyP40 peptidyl-prolyl isomerase cyclophilin 40
- one aspect of the invention concerns a method for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, the method comprising administering an effective amount of CyP40, or a biologically-active fragment thereof, to a subject in need thereof.
- Another aspect of the invention concerns a method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of CyP40, or a biologically-active fragment thereof, in vitro or in vivo.
- Another aspect of the invention concerns a composition
- a composition comprising CyP40, or a biologically-active fragment thereof; and an agent effective for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation.
- FIGS. 1A-1D An initial screen of peptidyl-prolyl isomerases identifies CyP40 disaggregase capacity.
- FIG. 1A shows a schematic representation of the hypothesized mechanism showing amyloid-forming protein monomer aggregating into an ordered mature amyloid fibril.
- PPIases peptidyl-prolyl isomerases
- key proline residues at structurally important locations may be isomerized leading to destabilization of secondary structure and subsequent disaggregation.
- FIG. 1C shows a bar graph representation of the time point 3 hours post addition of PPIase.
- FIG. 1D shows 60,000 ⁇ transmission electron microscopy of fibrils (left) showed linear and curved fibrils while CyP40 treated fibrils (right) were amorphous and lack linear structure (scale bar 400 nm and 600 nm for inset).
- FIGS. 2A-2K CyP40 lowered insoluble tau and oligomeric tau levels and promoted neuronal health in a mouse model overexpressing P301L tau.
- FIG. 2A shows a schematic depicting the timeline of rTg4510 pathology and experimental design.
- CyP40 disaggregates A53T ⁇ -synuclein, but not A ⁇ 42 mature fibrils.
- FIG. 3B shows transmission electron microscopy (TEM) images of A53T ⁇ -synuclein fibrils with or without addition of CyP40 (60,000 ⁇ magnification, scale bar 400 nm) ( FIG.
- TEM transmission electron microscopy
- FIG. 3C ThT fluorescence of A ⁇ 42 fibrils was not significantly affected by CyP40 treatment.
- FIG. 3D shows TEM of mature A ⁇ 42 fibrils showed no apparent change in morphology following CyP40 co-incubation (60,000 ⁇ magnification, scale bar 400 nm).
- FIGS. 3E-1 and 3E-2 show NTA of tau fibrils incubated with CyP40 shows less aggregate populations in the 300-850 nm range.
- FIGS. 3F-1 and 3F-2 show NTA of A53T ⁇ -synuclein fibrils incubated with CyP40 shows a lack of aggregate populations in the 200-450 nm range.
- FIGS. 3G-1 and 3G-2 show NTA did not reveal an apparent change in size distribution of fibrils between A ⁇ 42 control and CyP40-treated samples.
- FIGS. 4A-4F CyP40-mediated disaggregation depends on prolyl-isomerase activity of the enzyme as shown in vitro and in an inducible cell model overexpressing P301L tau.
- FIG. 4A shows results of a coupled chymotrypsin assay, revealing isomerase activity in wild-type (wt) CyP40, but not mutant (mut) CyP40 as compared to the no enzyme control.
- FIG. 4B shows that circular dichroism did not show differences between wt CyP40 and mut CyP40 secondary structures.
- FIG. 4D Transmission electron microscopy showed straight and curved mature tau fibers 300-600 nm in length that were disintegrated by co-incubation with wt CyP40, but not mut CyP40 treatment (scale bar 400 nm, 200 nm inset).
- FIG. 4E shows inducible HEK cells overexpressing tau P301L (iHEK-P301L) that were induced on day 1 show increasing insoluble tau levels after 11 days of overexpression.
- Vector-transfected and mut CyP40-transfected cells did not affect insoluble tau levels, while wt CyP40-transfected cells showed a decrease in insoluble tau levels as depicted in line graph ( FIG. 4F ).
- SEQ ID NO:1 is an amino acid sequence of a human CyP40 polypeptide: mshpspqakp snpsnprvff dvdiggervg rivlelfadi vpktaenfra lctgekgigh ttgkplhfkg cpfhriikkf miqggdfsnq ngtggesiyg ekfedenfhy khdregllsm anagrntngs qffittvptp hldgkhvvfg qvikgigvar ilenvevkge kpaklcviae cgelkegddg gifpkdgsgd shpdfpedad idlkdvdkil litedlknig ntffksqnwe maikkyaevl ryvdsskavi etadraklqp ialscvlnig acklkms
- the present invention concerns materials and methods for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof.
- CyP40 peptidyl-prolyl isomerase cyclophilin 40
- one aspect of the invention concerns a method for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, the method comprising administering an effective amount of CyP40, or a biologically-active fragment thereof, to a subject in need thereof.
- the method prior to said administering, the method further comprises identifying the subject as having a neurodegenerative disease or condition associated amyloid fibril aggregation.
- Methods for diagnosing neurodegenerative diseases or conditions are known in the art can be utilized, such as imaging and other tests (30-32).
- Another aspect of the invention concerns a method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of CyP40, or a biologically-active fragment thereof, in vitro or in vivo.
- Another aspect of the invention concerns a composition
- a composition comprising CyP40, or a biologically-active fragment thereof; and an agent effective for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation.
- the CyP40 polypeptide is human CyP40 (SEQ ID NO:1), or a biologically active fragment or variant thereof.
- a method of the invention for treating or preventing a neurodegenerative disease or a condition associated with aggregation of amyloid fibrils comprises administering an effective amount of CyP40, or a biologically-active fragment or variant thereof, or a polynucleotide encoding the same, to a human or animal subject in need thereof.
- the disease or condition is characterized the presence of neurofibrillary aggregates of proline-containing fibrils.
- the disease or condition is characterized by the presence of neurofibrillary aggregates of protein tau and/or ⁇ -synuclein in a cell, such as a neuronal or glial cell.
- Diseases and conditions contemplated within the scope of the invention include, but are not limited to, Alzheimer's disease, gangliogliomas and gangliocytomas, argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, frontotemporal dementia with parkinsonism linked to chromosome17, Pick's disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease (type C), Parkinsonism-dementia complex of Guam, postencephalitic parkinsonism, prion diseases (some), progressive subcortical gliosis, and progressive supranuclear palsy.
- the disease or condition may be early onset or late onset.
- the disease may be early onset, late onset, or familial Alzheimer's disease.
- CyP40 is administered to the human or non-human animal subject or is delivered to a target cell in the subject via a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment or variant thereof.
- the CyP40 polypeptide is a human CyP40 (GenBank Accession No. Q08752, version Q08752.3 GI:729274).
- the human CyP40 polypeptide comprises the amino acid sequence of SEQ ID NO:1, or a biologically active fragment or variant thereof.
- a method of the invention comprises injecting (e.g., via stereotaxic injection) a polynucleotide expression construct of the invention comprising a polynucleotide encoding a CyP40 polypeptide directly into neural tissue and/or cells of a human or non-human animal subject.
- the expression construct is an adeno-associated viral construct.
- other biologically active agents such as drugs and therapeutics, useful in treating neurodegenerative diseases and conditions can also be administered to the human or animal.
- the other drugs and therapeutics can be administered to the human or animal prior to, at the same time (co-administered), or subsequent to administration of the CyP40 polypeptide or polynucleotide encoding the same.
- drugs or therapeutics examples include, but are not limited to, donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Akatinol), and L-dopa.
- the other biologically active agent is another agent that is effective in treating or preventing a neurodegenerative disease, such as those associated with amyloid fibril aggregation.
- the other biologically active agent is another agent having fibril disaggregation activity, such as chaperone Hsp70.
- the other biologically active agent is a polypeptide having disaggregation activity, such as a chaperone Hsp70 polypeptide, and the other biologically active agent is coupled to a CyP40 polypeptide, or a biologically active fragment thereof, as a complex, and the polypeptide complex, or polynucleotide encoding the polypeptide complex, is administered to the subject or brought into contact with the amyloid fibrils in vitro or in vivo.
- the subject invention also concerns a method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of CyP40, or a biologically active fragment thereof, in vitro or in vivo.
- the neurofibrillary aggregates comprise proline-containing fibrils.
- the neurofibrillary aggregates comprise protein tau and/or ⁇ -synuclein.
- a CyP40 polypeptide, or a biologically active fragment or variant thereof, or a polynucleotide encoding the same is contacted with or provided to a target cell.
- the target cell can be a neuron or a glial cell.
- a CyP40 polypeptide is delivered to the target cell via a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment or variant thereof.
- the CyP40 polypeptide is a human CyP40 polypeptide.
- the human CyP40 polypeptide comprises the amino acid sequence of SEQ ID NO:1, or a biologically active fragment or variant thereof.
- a method of the invention comprises injecting (e.g., via stereotaxic injection) a polynucleotide expression construct of the invention comprising a polynucleotide encoding a CyP40 polypeptide directly into neural tissue or cells of a human or non-human animal subject.
- the expression construct is an adeno-associated viral construct.
- An expression construct of the invention can be designed to provide for constitutive expression of a CyP40 polypeptide in a target cell or tissue.
- other biologically active agents such as drugs and therapeutics useful in methods for disaggregating neurofibrillary aggregates in a target cell can also be contacted or provided to a target cell.
- the other biologically active agents can be provided or contacted prior to, at the same time (co-administered), or subsequent to administration of the CyP40 polypeptide or polynucleotide encoding the same.
- examples of other drugs or therapeutics that can be administered include, but are not limited to, paclitaxel, a statin, lithium, inhibitors of cyclin-dependent kinase 5, and methylthionine chloride.
- compositions comprising i) a CyP40 polypeptide, or a biologically active fragment or variant thereof, and/or ii) a polynucleotide encoding an a CyP40 polypeptide, or a biologically active fragment or variant thereof.
- the polynucleotide can be an expression construct that provides for expression of a CyP40 polypeptide in a target cell.
- the CyP40 polypeptide is a human CyP40 polypeptide.
- the human CyP40 polypeptide comprises the amino acid sequence of SEQ ID NO:1, or a biologically active fragment or variant thereof.
- compositions of the invention can also comprise other biologically active agents such as drugs or therapeutics, examples of which include, but are not limited to, donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Akatinol), paclitaxel (Taxol), a statin, lithium, inhibitors of cyclin-dependent kinase 5, methylthionine chloride, and L-dopa.
- drugs or therapeutics examples of which include, but are not limited to, donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Akatinol), paclitaxel (Taxol), a statin, lithium, inhibitors of cyclin-dependent kinase 5, methylthionine chloride, and L-dopa.
- polypeptides and polynucleotides in the composition, and/or administered to the subject are in isolated form.
- the polypeptides of the present invention can be formulated into pharmaceutically-acceptable salt forms.
- Pharmaceutically acceptable salt forms include the acid addition salts and include hydrochloric, hydrobromic, nitric, phosphoric, carbonic, sulphuric, and organic acids like acetic, propionic, benzoic, succinic, fumaric, mandelic, oxalic, citric, tartaric, maleic, and the like.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, and magnesium salts.
- compositions of the polypeptides of the invention can be prepared using conventional techniques.
- the subject invention also concerns polynucleotide expression constructs that comprise a polynucleotide of the present invention comprising a nucleotide sequence encoding a CyP40 polypeptide of the present invention.
- the CyP40 polypeptide is a human CyP40 polypeptide.
- the polynucleotide encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:1, or a fragment or variant thereof that exhibits CyP40's disaggregation activity.
- operably linked refers to a juxtaposition of the components described wherein the components are in a relationship that permits them to function in their intended manner. In general, operably linked components are in contiguous relation.
- Expression constructs of the invention will also generally include regulatory elements that are functional in the intended host cell in which the expression construct is to be expressed.
- regulatory elements include promoters, transcription termination sequences, translation termination sequences, enhancers, and polyadenylation elements.
- An expression construct of the invention can comprise a promoter sequence operably linked to a polynucleotide sequence encoding a polypeptide of the invention. Promoters can be incorporated into a polynucleotide using standard techniques known in the art. Multiple copies of promoters or multiple promoters can be used in an expression construct of the invention. In a preferred embodiment, a promoter can be positioned about the same distance from the transcription start site as it is from the transcription start site in its natural genetic environment. Some variation in this distance is permitted without substantial decrease in promoter activity. A transcription start site is typically included in the expression construct.
- an expression construct of the invention can comprise suitable promoters that can drive transcription of the polynucleotide sequence.
- promoters such as, for example, actin promoter, metallothionein promoter, NF-kappaB promoter, EGR promoter, SRE promoter, IL-2 promoter, NFAT promoter, osteocalcin promoter, SV40 early promoter and SV40 late promoter, Lck promoter, BMP5 promoter, TRP-1 promoter, murine mammary tumor virus long terminal repeat promoter, STAT promoter, or an immunoglobulin promoter can be used in the expression construct.
- the expression construct comprises a promoter that can drive expression of a polynucleotide of the invention in neuronal or glial cells.
- Promoters effective in neurons that can be used in the present invention include gamma-aminobutyric acid type A receptor ⁇ 1 subunit promoter (U.S. Pat. No. 6,066,726), zebrafish HuC promoter (U.S. Published Application No. 20040093630), and cellular adhesion molecule ICAM-4 promoter (U.S. Pat. No. 5,753,502) (see also U.S. Pat. No. 6,040,172).
- Expression constructs of the invention may optionally contain a transcription termination sequence, a translation termination sequence, signal polypeptide sequence, and/or enhancer elements.
- Transcription termination regions can typically be obtained from the 3′ untranslated region of a eukaryotic or viral gene sequence. Transcription termination sequences can be positioned downstream of a coding sequence to provide for efficient termination.
- Signal polypeptides are a group of short amino terminal sequences that encode information responsible for the relocation of an operably linked polypeptide to a wide range of post-translational cellular destinations, ranging from a specific organelle compartment to sites of protein action and the extracellular environment.
- Chemical enhancers are cis-acting elements that increase gene transcription and can also be included in the expression construct. Chemical enhancer elements are known in the art, and include, but are not limited to, the CaMV 35S enhancer element, cytomegalovirus (CMV) early promoter enhancer element, and the SV40 enhancer element. DNA sequences which direct polyadenylation of the mRNA encoded by the structural gene can also be included in the expression construct.
- CMV cytomegalovirus
- Vector refers to any genetic element, including for example, plasmids, cosmids, chromosomes, phage, virus, and the like, which is capable of replication when associated with proper control elements and which can transfer polynucleotide sequences between cells.
- Vectors contain a nucleotide sequence that permits the vector to replicate in a selected host cell.
- a number of vectors are available for expression and/or cloning, and include, but are not limited to, pBR322, pUC series, M13 series, and pBLUESCRIPT vectors (Stratagene, La Jolla, Calif.).
- a specific vector contemplated by the present invention is an adeno-associated virus.
- Polynucleotides, vectors, and expression constructs of the subject invention can be introduced into a cell by methods known in the art. Such methods include transfection, microinjection, electroporation, lipofection, cell fusion, calcium phosphate precipitation, and by biolistic methods.
- a polynucleotide or expression construct of the invention can be introduced in vivo via a viral vector such as adeno-associated virus (AAV), herpes simplex virus (HSV), papillomavirus, adenovirus, and Epstein-Barr virus (EBV). Attenuated or defective forms of viral vectors that can be used with the subject invention are known in the art.
- AAV adeno-associated virus
- HSV herpes simplex virus
- papillomavirus papillomavirus
- adenovirus Epstein-Barr virus
- polynucleotides, vectors, and expression constructs of the invention can also be introduced in vivo via lipofection (DNA transfection via liposomes prepared from synthetic cationic lipids) (Felgner et al., 1987). Synthetic cationic lipids (LIPOFECTIN, Invitrogen Corp., La Jolla, Calif.) can be used to prepare liposomes to encapsulate a polynucleotide, vector, or expression construct of the invention.
- a polynucleotide, vector, or expression construct of the invention can also be introduced in vivo as naked DNA using methods known in the art, such as transfection, microinjection, electroporation, calcium phosphate precipitation, and by biolistic methods.
- polynucleotides and polypeptides of the subject invention can also be defined in terms of more particular identity and/or similarity ranges with those sequences exemplified herein, such as SEQ ID NO:1.
- sequence identity with sequences exemplified herein, such as SEQ ID NO:1 will typically be greater than 60%, preferably greater than 75%, more preferably greater than 80%, even more preferably greater than 90%, and can be greater than 95%.
- the identity and/or similarity of a sequence can be 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% as compared to a sequence exemplified herein, such as SEQ ID NO:1.
- the subject invention also contemplates those polynucleotide molecules (encoding polypeptides of the invention) having sequences which are sufficiently homologous with the polynucleotide sequences encoding a polypeptide of the invention so as to permit hybridization with that sequence under standard stringent conditions and standard methods (Maniatis, T. et al., 1982).
- stringent conditions for hybridization refers to conditions wherein hybridization is typically carried out overnight at 20-25 C below the melting temperature (Tm) of the DNA hybrid in 6 ⁇ SSPE, 5 ⁇ Denhardt's solution, 0.1% SDS, 0.1 mg/ml denatured DNA. The melting temperature is described by the following formula (Beltz, G.A. et al., 1983):
- Tm 81.5 C+16.6 Log[Na+]+0.41(%G+C) ⁇ 0.61(% formamide) ⁇ 600/length of duplex in base pairs.
- Washes are typically carried out as follows:
- the biologically active variant has one or both of the following characteristics: retains prolyl isomerase activity, and retains the isomerase domain.
- the biologically active variant is a biologically active variant of human CyP40 (SEQ ID NO:1) that has one or more of the following characteristics: retains prolyl isomerase activity; retains the isomerase domain; and greater than 60%, greater than 75%, greater than 80%, greater than 90%, greater than 95% sequence identity, or greater than 98% sequence identity to SEQ ID NO:1.
- SEQ ID NO:1 biologically active variant of human CyP40 (SEQ ID NO:1) that has one or more of the following characteristics: retains prolyl isomerase activity; retains the isomerase domain; and greater than 60%, greater than 75%, greater than 80%, greater than 90%, greater than 95% sequence identity, or greater than 98% sequence identity to SEQ ID NO:1.
- the structure of human CyP40 protein has been described and is incorporated herein by reference in its entirety (27, 33-34).
- the subject invention also contemplates biologically active fragments of full-length CyP40 polypeptides and polynucleotides that encode such fragments.
- the biologically active fragment has one or both of the following characteristics: retains prolyl isomerase activity, and retains the isomerase domain.
- the biologically active fragment is a biologically active fragment of full length human CyP40 (SEQ ID NO:1) that has one or both of the following characteristics: retains prolyl isomerase activity, and retains the isomerase domain (27, 33-34).
- biologically active refers to CYP40's amyloid fibril disaggregation activity. Methods for determining the capacity for disaggregation activity, which may be used for assessing variant and fragment sequences, are described herein.
- biologically active agent refers to agents such as drugs and biologics that are non-inert and have some effect on the body.
- nucleic acid refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally-occurring nucleotides.
- the polynucleotide sequences include both the DNA strand sequence that is transcribed into RNA and the RNA sequence that is translated into protein.
- the polynucleotide sequences include both full-length sequences as well as shorter sequences derived from the full-length sequences (e.g., biologically active fragments).
- polynucleotide sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell.
- the polynucleotide sequences falling within the scope of the subject invention further include sequences which specifically hybridize with the sequences coding for a polypeptide of the invention.
- the polynucleotide includes both the sense and antisense strands as either individual strands or in the duplex.
- an effective amount of a polypeptide, polynucleotide, and/or composition of the present invention is administered to a subject having a neurodegenerative disorder or condition associated with amyloid fibril aggregation and who is in need of treatment thereof.
- the subject can be a human or other mammal, such as a dog, cat, or horse, or other animals having the disorder.
- Means for administering and formulating polypeptides and polynucleotides for administration to a patient are known in the art, examples of which are described herein.
- Polypeptides, polynucleotides, and/or compositions of the invention can be delivered to a cell either through direct contact of polypeptide or polynucleotide with the cell or via a carrier means.
- a polypeptide or polynucleotide of the invention comprises an attached group that enhances cellular uptake of the polypeptide.
- the polypeptide or polynucleotide is attached to an antibody that binds to a targeted cell.
- the polypeptide or polynucleotide is encapsulated in a liposome.
- Polypeptides can also be delivered using a polynucleotide that encodes a subject polypeptide. Any polynucleotide having a nucleotide sequence that encodes a polypeptide of the invention is contemplated within the scope of the invention.
- the polynucleotide is delivered to the cell where it is taken up and the polynucleotide is transcribed into RNA and the RNA is translated into the encoded polypeptide.
- polypeptides and polynucleotides can be administered by any suitable route known in the art including, for example, oral, intramuscular, intraspinal, intracranial, nasal, rectal, parenteral, subcutaneous, or intravenous routes of administration.
- Administration of the polypeptides and polynucleotides of the invention can be continuous or at distinct intervals as can be readily determined by a person skilled in the art.
- compositions useful in the subject invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations are described in detail in a number of sources which are well known and readily available to those skilled in the art. For example, Remington's Pharmaceutical Science by E.W. Martin describes formulations which can be used in connection with the subject invention. In general, the compositions of the subject invention will be formulated such that an effective amount of the bioactive polypeptide or polynucleotide is combined with a suitable carrier in order to facilitate effective administration of the composition. The compositions used in the present methods can also be in a variety of forms.
- compositions include, for example, solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspension, suppositories, injectable and infusible solutions, and sprays.
- solid dosage forms such as tablets, pills, powders, liquid solutions or suspension, suppositories, injectable and infusible solutions, and sprays.
- the preferred form depends on the intended mode of administration and therapeutic application.
- the compositions also preferably include conventional pharmaceutically acceptable carriers and diluents which are known to those skilled in the art.
- Examples of carriers or diluents for use with the subject polypeptides and polynucleotides include, but are not limited to, water, saline, oils including mineral oil, ethanol, dimethyl sulfoxide, gelatin, cyclodextrans, magnesium stearate, dextrose, cellulose, sugars, calcium carbonate, glycerol, alumina, starch, and equivalent carriers and diluents, or mixtures of any of these.
- Formulations of the polypeptide or polynucleotide of the invention can also comprise suspension agents, protectants, lubricants, buffers, preservatives, and stabilizers.
- compositions of the invention will advantageously comprise between about 0.1% and 45%, and especially, 1 and 15% by weight of the total of one or more of the polypeptide or polynucleotide based on the weight of the total composition including carrier or diluent.
- the compounds and molecules of the subject invention can also be administered utilizing liposome technology, slow release capsules, implantable pumps, and biodegradable containers. These delivery methods can, advantageously, provide a uniform dosage over an extended period of time.
- the subject polypeptides and polynucleotides of the invention can also be modified by the addition of chemical groups, such as PEG (polyethylene glycol).
- PEG polyethylene glycol
- PEGylated polypeptides typically generate less of an immunogenic response and exhibit extended half-lives in vivo in comparison to polypeptides that are not PEGylated when administered in vivo.
- Methods for PEGylating proteins and polypeptides known in the art see, for example, U.S. Pat. No. 4,179,337).
- the subject polypeptides and polynucleotides can also be modified to improve cell membrane permeability.
- cell membrane permeability can be improved by attaching a lipophilic moiety, such as a steroid, to the polypeptide or polynucleotide.
- a lipophilic moiety such as a steroid
- Other groups known in the art can be linked to polypeptides or polynucleotides of the present invention.
- the subject invention also concerns a packaged dosage formulation comprising in one or more packages, packets, or containers at least one polypeptide or polynucleotide and/or composition of the subject invention formulated in a pharmaceutically acceptable dosage.
- the package can contain discrete quantities of the dosage formulation, such as tablet, capsules, lozenge, and powders.
- the quantity of polypeptide or polynucleotide in a dosage formulation and that can be administered to a patient can vary from about 1 mg to about 5000 mg, or about 1 mg to about 2000 mg, or more typically about 1 mg to about 500 mg, or about 5 mg to about 250 mg, or about 10 mg to about 100 mg.
- kits comprising in one or more containers a composition, compound, or molecule of the present invention.
- a kit contains a polypeptide or polynucleotide of the present invention.
- a kit comprises a polypeptide comprising the amino acid sequence shown in SEQ ID NO:1, or a fragment or variant of the polypeptide that exhibits CyP40 disaggregation activity.
- a kit of the invention can also comprise one or more compounds, biological molecules, or drugs.
- a kit of the invention can comprise a polypeptide or polynucleotide of the invention, and optionally comprises one or more of a drug or composition used in treating a neurodegenerative disease or condition.
- drugs or therapeutics include, but are not limited to, donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Akatinol), paclitaxel (Taxol), a statin, lithium, inhibitors of cyclin-dependent kinase 5, methylthionine chloride, and L-dopa.
- Polypeptides having one or more substitutions of amino acids other than those specifically exemplified in the subject polypeptides are also contemplated within the scope of the present invention.
- one or more non-natural amino acids can be substituted for the amino acids of a polypeptide of the invention, so long as the polypeptide having substituted amino acids retains substantially the same activity as the polypeptide in which amino acids have not been substituted.
- non-natural amino acids include, but are not limited to, ornithine, citrulline, hydroxyproline, homoserine, phenylglycine, taurine, iodotyrosine, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, 2-amino butyric acid, ⁇ -amino butyric acid, ⁇ -amino hexanoic acid, 6-amino hexanoic acid, 2-amino isobutyric acid, 3-amino propionic acid, norleucine, norvaline, sarcosine, homocitrulline, cysteic acid, ⁇ -butylglycine, ⁇ -butylalanine, phenylglycine, cyclohexylalanine, ⁇ -alanine, fluoro-amino acids, designer amino acids such as ⁇ -methyl amino acids, C-methyl amino acids,
- Amino acids can be generally categorized in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby a polypeptide having an amino acid of one class is replaced with another amino acid of the same class fall within the scope of the subject invention so long as the polypeptide having the substitution still retains substantially the same biological activity as a polypeptide that does not have the substitution.
- Table 1 below provides a listing of examples of amino acids belonging to each class.
- the methods and compositions of the present invention can be used in the treatment of humans and non-human animals.
- the animals contemplated within the scope of the invention include domesticated, agricultural, or zoo- or circus-maintained animals.
- domesticated animals include, for example, dogs, cats, rabbits, ferrets, guinea pigs, hamsters, pigs, monkeys or other primates, and gerbils.
- Agricultural animals include, for example, horses, mules, donkeys, burros, cattle, cows, pigs, sheep, and alligators.
- Zoo- or circus-maintained animals include, for example, lions, tigers, bears, camels, giraffes, hippopotamuses, and rhinoceroses.
- treat is intended to mean administer an agent to a subject, such as a human or non-human mammal (for example, a non-human animal model), in order to prevent or delay a worsening of the effects of a condition, or to partially or fully reverse the effects of the condition, such as neurodegenerative disease or a condition associated with amyloid fibril aggregation.
- the condition is characterized by the presence of neurofibrillary aggregates of the microtubule associated protein tau and/or alpha-synuclein.
- prevent is intended to mean prophylaxis, or to reduce or minimize the chance that a subject who has an increased susceptibility for developing a condition will develop the condition, or to delay the onset of the condition, such as neurodegenerative disease or a condition associated with amyloid fibril aggregation.
- the condition is characterized by the presence of neurofibrillary aggregates of the microtubule associated protein tau and/or alpha-synuclein.
- an agent such as a polypeptide or a polynucleotide encoding the polypeptide
- an agent such as a polypeptide or a polynucleotide encoding the polypeptide
- the exact amount required will vary, depending on the subject, species, age, and general condition of the subject, the severity of disease (or underlying genetic defect) that is being treated, the particular agent used, its mode of administration, and the like.
- An appropriate “effective amount” may be determined by one of ordinary skill in the art using routine experimentation.
- isolated polypeptide or “purified polypeptide” is intended to mean a polypeptide (or a fragment thereof) that is substantially free from the materials with which the polypeptide is normally associated in nature.
- the polypeptides of the invention, or fragments thereof can be obtained, for example, by extraction from a natural source (for example, a mammalian cell), by expression of a recombinant nucleic acid encoding the polypeptide (for example, in a cell or in a cell-free translation system), or by chemically synthesizing the polypeptide.
- polypeptide fragments may be obtained by any of these methods, or by cleaving full-length proteins and/or polypeptides.
- peptide As used herein, the terms “peptide”, “polypeptide”, and “protein” are used interchangeably and intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 370 amino acid residues, polypeptides of more than 370 amino acid residues, and full-length proteins.
- the peptides may occur naturally or be synthetically constructed.
- isolated nucleic acid molecule As used herein, “isolated nucleic acid molecule”, “purified nucleic acid molecule”, or “isolated polynucleotide” or “purified polynucleotide” is intended to mean DNA that is free of the genes that, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene.
- the term therefore includes, for example, a recombinant DNA which is incorporated into or otherwise associated with a vector, such as an autonomously replicating plasmid or virus; or incorporated into the genomic DNA of a prokaryote or eukaryote (e.g., a transgene); or which exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR, restriction endonuclease digestion, or chemical or in vitro synthesis). It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.
- isolated nucleic acid molecule or “isolated polynucleotide” also refers to RNA, e.g., an mRNA molecule that is encoded by an isolated DNA molecule, or that is chemically synthesized, or that is separated or substantially free from at least some cellular components, for example, other types of RNA molecules or polypeptide molecules.
- Embodiment 1 A method for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, said method comprising administering an effective amount of peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof, to a human or animal subject in need thereof
- CyP40 peptidyl-prolyl isomerase cyclophilin 40
- Embodiment 2 The method according to embodiment 1, wherein said method further comprises identifying a subject as one in need of treatment.
- Embodiment 3 The method according to embodiment 1 or 2, wherein the disease or condition is characterized by the presence of neurofibrillary aggregates of the microtubule associated protein tau and/or ⁇ -synuclein.
- Embodiment 4 The method according to any one of embodiments 1 to 3, wherein the disease or condition is Alzheimer's disease, gangliogliomas, gangliocytomas, argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, frontotemporal dementia with parkinsonism linked to chromosome17, Pick's disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease (type C), Parkinsonism-dementia complex of Guam, postencephalitic parkinsonism, prion diseases, progressive subcortical gliosis, or progressive supranuclear palsy.
- the disease or condition is Alzheimer's disease, gangliogliomas, gangliocytomas, argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, frontotemporal dementia with parkinsonism linked to chromosome17, Pick's disease, Hallervorden-Spatz disease, my
- Embodiment 5 The method according to any one of embodiments 1 to 4, wherein the CyP40, or a biologically active fragment thereof, is administered to the subject orally, nasally, rectally, parenterally, subcutaneously, intramuscularly, intraspinal, intracranially, or intravenously.
- Embodiment 6 The method according to any one of embodiments 1 to 5, wherein the CyP40, or a biologically fragment thereof, is administered to the subject as a polynucleotide encoding the CyP40, or the biologically active fragment thereof.
- Embodiment 7 The method according to any one of embodiments 1 to 6, wherein the polynucleotide is provided in an expression construct.
- Embodiment 8 The method according to any one of embodiments 1 to 7, wherein the CyP40 is a human CyP40.
- Embodiment 9 The method according to embodiment 6, wherein the polynucleotide is injected directly into neural tissue and/or cells of the subject.
- Embodiment 10 The method according to embodiment 7, wherein the expression construct comprises a promoter that provides for expression of the polynucleotide in neurons or glial cells.
- Embodiment 11 The method according to embodiment 7, wherein the expression construct is an adeno-associated viral construct.
- Embodment 12 The method according to any one of embodiments 1 to 11, wherein said method further comprises administering a biologically active agent used in treating neurodegenerative diseases and/or conditions to the subject.
- Embodiment 13 The method according to embodiment 12, wherein the biologically active agent is administered prior to, or at the same time as, or subsequent to, administration of the CyP40, or the biologically active fragment thereof.
- Embodiment 14 The method according to embodiment 12 or 13, wherein the biologically active agent is one or more of donepezil, galantamine, rivastigmine, memantine, or L-dopa.
- the biologically active agent is one or more of donepezil, galantamine, rivastigmine, memantine, or L-dopa.
- Embodiment 15 The method according to any preceding embodiment, wherein the subject has the neurodegenerative disease or condition at the time of said administering, and the CyP40, or a biologically-active fragment thereof, is administered as therapy.
- Embodiment 16 The method according to any one of embodiments 1 to 14, wherein the subject does not have the neurodegenerative disease or condition at the time of said administering, and the CyP40, or a biologically-active fragment thereof, is administered as prophylaxis.
- Embodiment 17 A method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof, in vitro or in vivo.
- CyP40 peptidyl-prolyl isomerase cyclophilin 40
- Embodiment 18 The method of embodiment 17, wherein the neurofibrillary aggregates comprise microtubule associated protein tau and/or ⁇ -synuclein.
- Embodiment 19 The method according to embodiment 17 or 18, wherein said contacting is in vivo and comprises administering the CyP40, or a biologically active fragment thereof, to a human or animal subject, and wherein the CyP40, or a biologically active fragment thereof, is administered to the subject orally, nasally, rectally, parenterally, subcutaneously, intramuscularly, intraspinal, intracranially, or intravascularly (e.g., intravenously).
- Embodiment 20 The method according to any one of embodiments 17 to 19, wherein said contacting is in vivo and comprises administering the CyP40, or a biologically active fragment thereof, to a human or animal subject, and wherein the CyP40, or a biologically fragment thereof, is administered as a polynucleotide encoding the CyP40, or the biologically active fragment thereof.
- Embodiment 21 The method according to embodiment 20, wherein the polynucleotide is provided in an expression construct.
- Embodiment 22 The method according to any one of 17 to 21, wherein the CyP40 is a human CyP40.
- Embodiment 23 The method according to embodiment 20 or 21, wherein the polynucleotide is injected directly into neural tissue and/or cells of the subject.
- Embodiment 24 The method according to embodiment 23, wherein the expression construct comprises a promoter that provides for expression of the polynucleotide in neurons or glial cells.
- Embodiment 25 The method according to embodiment 21, wherein the expression construct is an adeno-associated viral construct.
- Embodiment 26 The method according to any one of embodiments 17 to 25, wherein said method further comprises administering a biologically active agent used in treating neurodegenerative diseases and/or conditions to the subject.
- Embodiment 27 The method according to embodiment 26, wherein the biologically active agent is administered prior to, or at the same time as, or subsequent to, administration of the CyP40, or the biologically active fragment thereof.
- Embodiment 28 The method according to embodiment 26, wherein the biologically active agent is one or more of donepezil, galantamine, rivastigmine, memantine, or L-dopa.
- Embodiment 29 A composition comprising a peptidyl-prolyl isomerase cyclophilin 40 (CyP40) polypeptide, or a biologically active fragment thereof or a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment thereof.
- CyP40 peptidyl-prolyl isomerase cyclophilin 40
- Embodiment 30 The composition of embodiment 29, wherein said composition comprises a physiologically acceptable buffer, carrier, and/or diluent.
- Embodiment 31 The composition of embodiment 29 or 30, further comprising an agent effective for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation.
- Embodiment 32 The composition of any one of embodiment 29 to 31, further comprising an agent having amyloid fibril disaggregation activity in vitro or in vivo.
- Embodiment 33 A packaged dosage formulation comprising at least one of i) a CyP40 polypeptide, or a biologically active fragment thereof and/or ii) a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment thereof; in a pharmaceutically acceptable dosage in one or more packages, packets, or containers.
- Embodiment 34 The packaged dosage formulation according to embodiment 33, wherein said CyP40 polypeptide or said polynucleotide is provided as a tablet, capsule, lozenge, or powder.
- Embodiment 35 The packaged dosage formulation according to embodiment 33, wherein said polynucleotide is provided in an expression construct.
- Embodiment 36 The packaged dosage formulation according to embodiment 35, wherein said expression construct comprises a promoter that provides for expression of said polynucleotide in neurons or glial cells.
- Embodiment 37 The packaged dosage formulation according to any one of embodiments 33 to 36, wherein said one or more packages, packets, or containers further comprise a biologically active agent useful in treating neurodegenerative disease or condition.
- Embodiment 38 The packaged dosage formulation according to any one of embodiments 33 to 37, wherein said one or more packages, packets, or contains further comprise a biologically active agent useful for disagreggating neurofibrillary aggregates.
- Embodiment 39 A kit comprising in one or more containers a CyP40 polypeptide, or a biologically active fragment thereof, and/or a polynucleotide encoding said CyP40 polypeptide, or said biologically active fragment thereof.
- Embodiment 40 The kit according to embodiment 39, wherein said polynucleotide is provided in an expression construct.
- Embodiment 41 The kit according to embodiment 40, wherein said expression construct comprises a promoter that provides for expression of said polynucleotide in neurons or glial cells.
- Embodiment 42 The kit according to embodiment 39, wherein said one or more containers further comprise a biologically active agent useful in treating neurodegenerative disease or condition.
- Embodiment 43 The kit according to embodiment 39, wherein said one or more containers further comprises a biologically active agent useful for disagreggating neurofibrillary aggregates.
- Embodiment 44 The method, composition, packaged dosage formulation, or kit according to any one of embodiments 1 to 43, wherein the CyP40 is human CyP40.
- Embodiment 45 The method, composition, packaged dosage formulation, or kit according to any one of embodiments 1 to 43, wherein the CyP40 comprises the amino acid sequence of SEQ ID NO:1.
- Pellets were then thawed on ice and subsequently lysed by sonication and spun at 50,000 ⁇ g for 1 hour. After filtration of the supernatant with a 0.02 ⁇ m filter, a standard gravity nickel column using Ni-NTA resin (Fisher #PI88222) was performed. TEV protease was then added to the elution fraction, placed into a 3,000 MW cutoff dialysis bag and into TEV buffer overnight at 4° C. The solution was then dialyzed back into nickel chromatography running buffer and a 2 nd nickel purification column was ran. We then performed size exclusion chromatography using a HiLoad 16/600 Superdex 200pg column and fractions were pooled and concentrated. Proteins were then dialyzed into appropriate buffer (PBS or Sodium Acetate). Proteins were estimated to be >95% pure by coomassie staining.
- Amyloid Beta protein fragment 42 was purchased from Sigma Aldrich (107761-42-2), and mature ⁇ -synuclein fibrils were a generous gift from Dr. Vladimir Uversky at USF.
- Fibril formation 50 ⁇ M recombinant human tau P301L was incubated in the presence of 12.5 ⁇ M low molecular weight heparin (4:1 molar ratio) at 37° C. in 100 mM Sodium Acetate pH 7.0 buffer without agitation for 7 days. Thioflavin T fluorescence was recorded throughout fibrillation in order to confirm plateau of fluorescence. A ⁇ 42 fibrils were formed by suspending the lyophilized protein in minimal 60 mM NaOH and then diluting to a final concentration of 50 ⁇ M in PBS buffer. The solution was then shaken at 700 rpm at 37° C. for 5 days.
- Nanoparticle tracking analysis At the end of experiments, samples were diluted 10,000 fold into 1 mL of deionized filtered water (0.02 ⁇ m). Approximately 300 ⁇ L sample was loaded onto the Malvern Nanosight LM10 equipped with a 633 nm red laser. Protein particle data was captured with a Marlin CCD camera in duplicate. Between samples, 500 ⁇ L of water was passed through the imaging chamber to clear previous sample. Graphs were generated by Nanosight software.
- Circular dichroism (CD) spectroscopy Far-UV CD measurements were taken using a JASCO J-815 spectropolarimeter. Wt CyP40 and mut CyP40 were dialyzed into 10 mM sodium phosphate buffer, pH 7.5. Proteins were loaded into a 1 mm quartz cuvette and readings were taken at 25° C. Each spectrum is an average of 3 scans from 190-260 nm at 50 nm/min. Buffer spectral curves were subtracted for each protein.
- Chymotrypsin-coupled assay PPIase activity was measured by a chymotrypsin-coupled assay using a synthetic peptide succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma) as previously described [28] with some modifications. Briefly, the reactions were set up in precooled 1 ml reaction buffer (50 mM Tris-HC1, pH 7.5, 150 mM NaCl, 10 mM CaCl 2 ) by adding 5 ⁇ l 1 mM peptide, 1 ⁇ l chymotrypsin (1 mg/ml, Sigma), and 0.5 ⁇ M purified protein. The absorbance was measured every 20 seconds for 10 min at 410 nm in a Genesys 10S UV-Vis spectrophotometer (Thermo) at 4° C.
- Tetracycline inducible HEK293 cell line was generated by the insertion of human P301L tau 4R0N DNA into a pCDNA 4/TO plasmid vector (Invitrogen).
- the tau/TO plasmid construct was transfected into the T-RExTM HEK cell line (Invitrogen) which stably express the tetracycline repressor protein. After zeocin selection (200 ⁇ g/ml), the colonies were picked up and the expression of Tau was detected by Western blot with and without tetracycline (1 ⁇ g/ml).
- GFP green fluorescent protein
- Tissue was stained free floating as previously described [29].Tissue sections were incubated in PBS supplemented with 10% MeOH and 3% H 2 O 2 to block endogenous peroxidases. Following PBS washes, tissue was permeabilized by 0.2% Triton-X-100 with 1.83% lysine and 4% serum in PBS for 30 minutes. Tissue was then incubated at room temperature overnight in primary antibody. The following primary antibodies were used, anti-CyP40 (1:2000), T22 (1:700), and anti-H150 tau (1:30000). Following three PBS washes, biotinylated goat anti-rabbit (Southern Biotech) secondary (1:10000) was added for 2 hours.
- Sections stained for stereology were blocked and permeabilized as described above and incubated overnight with biotinylated NeuN (1:3000) at room temperature. Following PBS washes, ABC conjugation, and peroxidase development tissue was mounted on glass slides and dried overnight. These sections were then counter-stained with cresyl violet (nissl) by incubating with 0.05% cresyl violet briefly and then quickly destaining with 0.3% acetic acid in water prior to dehydration.
- tissue slices were mounted on glass slides and dried overnight. These slides were then incubated in a 0.003% potassium permanganate solution for 10 min. After rinsing with water the sections were incubated from 1-2 min in a 2.0% oxalic acid solution then rinsed thoroughly in water. Slides were then incubated in a 5.0% sodium metaperiodate solution for 5 min and again rinsed in water. Slides were then treated with an alkaline silver iodide solution (1 M sodium hydroxide, 0.6 M potassium iodide, 0.053% silver nitrate) for 1 min, then rinsed three times with a 0.5% acetic acid solution.
- an alkaline silver iodide solution (1 M sodium hydroxide, 0.6 M potassium iodide, 0.053% silver nitrate
- Staining was developed by combining solutions A (5% sodium carbonate), B (0.024 M ammonium nitrate, 0.012 M silver nitrate, 0.003 M tungstosilicic acid), and C (0.024 M ammonium nitrate, 0.012 M silver nitrate, 0.003 M tungstosilicic acid, 0.25% formaldehyde) in a 2:1:1 ratio, adding B and C to solution A and incubating for 10-30 min. The slides were then rinsed three times in 0.5% acetic acid, then water. The slides were then incubated in gold tone for 3-4 min and again rinsed in water, then a 1% sodium thiosulphate solution for 5 min and a final rinse in water before they were dehydrated and coverslipped using DPX.
- solutions A 5% sodium carbonate
- B 0.024 M ammonium nitrate, 0.012 M silver nitrate, 0.003 M tungstosilicic acid
- C 0.024 M ammonium nitrate,
- Tissue imaging and quantification A slide scanning microscope (Zeiss) was used to image all tissue. Bright field analysis was performed using Zeiss Neuroquant IAE analysis software. This program was used to outline regions of interest from the entire slide. Then, thresholds were set manually until only positive cells, as determined by the analyzer, were selected with as little non-specific areas selected as possible. Using the batch process option, the Area Ratio of positive cells within the regions of interest was automatically calculated for each stained group.
- Example 1 CyP40 Disaggregates Amyloid Fibrils In Vitro
- amyloidogenesis is significantly affected by structurally flexible proline residues (9,10). Because ⁇ -turns are often associated with proline residues (11), the inventors speculated that enzymes capable of twisting these prolines could unravel amyloid structures.
- the family of cis/trans peptidyl prolyl isomerases (PPIases) is diverse (12), and perhaps most importantly does not require the use of ATP to isomerize proline residues (13). While prolyl isomerization has been implicated in the formation and prevention of protein aggregation (14,15), a role for PPIases in amyloid disaggregation has never been described. Therefore, the inventors hypothesized that discrete PPIases may be able to disaggregate mature amyloid fibrils in a proline-dependent and energy-independent manner ( FIG. 1A ).
- Example 2 CyP40 Disaggregates Amyloid Fibrils in vivo
- the disaggregase capacity of CyP40 was then evaluated in a mouse model overexpressing P301L tau to determine if the in vitro disaggregase activity of the PPIase had physiological relevance.
- Hippocampi of rTg4510 mice were injected at 6 months of age with AAV9-GFP or AAV9-CyP40 and harvested at 8 months for histological analysis ( FIG. 2A ). These ages were chosen so that the disaggregation activity of CyP40 on preformed, mature tau fibrils could be investigated. However, these time points came at the cost of not being able to discern meaningful differences in behavior given the severe hippocampal volume loss observed in these mice by 6-8 months (16-18). CyP40 overexpression significantly decreased relative insoluble tau levels by western blot ( FIGS. 2B and 2C ), to a level similar to that of a 1-3 month old rTg4510 mouse [19].
- ThT fluorescence and TEM were then used to examine the effects of CyP40 on disaggregation of pre-formed aggregates of other amyloidogenic substrates, including A53T ⁇ -synuclein and the ⁇ -amyloid 1-42 peptide (A ⁇ 42), pathological hallmarks of Parkinson's disease (PD) and Alzheimer's disease (AD), respectively. While ⁇ -synuclein contains proline residues similar to tau, A ⁇ 42 does not, permitting insight into the proline dependence of this mechanism.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
- The present application claims the benefit of U.S. Provisional Application Ser. No. 62/329,317, filed Apr. 29, 2016, which is hereby incorporated by reference herein in its entirety, including any figures, tables, nucleic acid sequences, amino acid sequences, or drawings.
- This invention was made with government support NS073899 awarded by National Institutes of Health. The government has certain rights in the invention.
- Protein complexes with disaggregase activity have recently been discovered in eukaryotic organisms. Disaggregation is important because many diseases result from aberrant protein aggregation, particularly in the brain. Hsp104 and cpSRP43 possess disaggregation activity, but there are no known mammalian orthologues [1]. More recently, it was shown that the chaperone Hsp70 works in a multi-protein complex with ATP to promote disaggregation of various amyloidogenic substrates.
- Many mammalian proteins have intrinsic sequences that promote amyloid fibril formation. This is believed to be a natural process to allow proteins to autonomously prevent the formation of more toxic amorphous intermediate structures (2,3). However, in some cases such as neurodegenerative disease, amyloid formation is an aberrant process that can promote proteotoxicity (4). Recent evidence suggests endogenous protein complexes have the ability to dissolve these potentially toxic amyloidogenic structures (5). This work has not only shed light on novel endogenous pathways of disaggregation, but also suggests that these proteins could be exploited to mitigate disease pathogenesis. For example, the yeast disaggregase Hsp104 utilized ATP hydrolysis to disaggregate a variety of human proteins in a yeast model (6,7). More recently, the metazoan Hsp70/DnaJ/Hsp110 complex was found to work with ATP to disaggregate amyloid substrates in vitro (8). However, the dynamic and ubiquitous nature of aggregation and disaggregation in cells suggests that a more energy-efficient process might exist, one that does not require ATP.
- The peptidyl-prolyl isomerase cyclophilin 40 (CyP40), encoded by the PPID gene, has been identified to be an ATP-independent human disaggregase. CyP40, independent of any co-factors, dissolved fibrillized aggregates of two disease-relevant amyloids: the microtubule associated protein tau and α-synuclein. Overexpression of CyP40 in the rTg4510 tau transgenic mouse brain was neuroprotective and decreased fibrillar and oligomeric tau species. The disaggregating activity of CyP40 appeared selective for those proteins possessing proline residues, and was dependent on the prolyl isomerase activity of the enzyme. This work shows that a low energy human disaggregase can independently and selectively protect neurons from proteotoxicity in the mammalian brain.
- The present invention concerns compositions and methods for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof.
- Thus, one aspect of the invention concerns a method for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, the method comprising administering an effective amount of CyP40, or a biologically-active fragment thereof, to a subject in need thereof.
- Another aspect of the invention concerns a method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of CyP40, or a biologically-active fragment thereof, in vitro or in vivo.
- Another aspect of the invention concerns a composition comprising CyP40, or a biologically-active fragment thereof; and an agent effective for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation.
-
FIGS. 1A-1D . An initial screen of peptidyl-prolyl isomerases identifies CyP40 disaggregase capacity.FIG. 1A shows a schematic representation of the hypothesized mechanism showing amyloid-forming protein monomer aggregating into an ordered mature amyloid fibril. Upon the addition of peptidyl-prolyl isomerases (PPIases), key proline residues at structurally important locations may be isomerized leading to destabilization of secondary structure and subsequent disaggregation.FIG. 1B depicts Thioflavin T fluorescence measured 3 hours after CyP40 addition, revealed a significant decrease in fluorescence (p=0.0020), while the addition of CyPA, FKBP51, or FKBP52 did not produce significant differences.FIG. 1C shows a bar graph representation of thetime point 3 hours post addition of PPIase.FIG. 1D shows 60,000×transmission electron microscopy of fibrils (left) showed linear and curved fibrils while CyP40 treated fibrils (right) were amorphous and lack linear structure (scale bar 400 nm and 600 nm for inset). -
FIGS. 2A-2K . CyP40 lowered insoluble tau and oligomeric tau levels and promoted neuronal health in a mouse model overexpressing P301L tau.FIG. 2A shows a schematic depicting the timeline of rTg4510 pathology and experimental design.FIG. 2B shows results of a Western blot comparing the insoluble (Ins) and soluble (Sol) fractions from hippocampi of AAV9-GFP (n=8) and AAV9-CyP40 (n=8) injected mice.FIG. 2C shows quantification of the relative insoluble tau levels fromFIG. 2B indicated a significant decrease in CyP40 treated mice (p=0.0016,scale bar 2000 μm and 500 μm for inset).FIGS. 2D and 2E show levels of total tau were significantly reduced in CyP40 treated mice (p=0.0011,scale bar 2000 μm and 500 μm for inset).FIGS. 2F and 2G show results of Gallyas silver staining of hippocampal sections from GFP and CyP40 injected mice revealed a significant decrease in silver-positive tau (p=0.0228,scale bar 2000 μm and 500 μm for inset).FIGS. 2H and 2I show levels of oligomeric tau, as measured by the T22 antibody, were significantly decreased (p=0.0011) following CyP40 treatment (scale bar 2000 μm and 500 μm for inset).FIGS. 2J and 2K show results of unbiased stereology, indicating a significant increase in the number of CA1 neurons in CyP40 treated hippocampi (p=0.0001, scale bar 125 μm). -
FIGS. 3A, 3B, 3C, 3D, 3E-1, 3E-2, 3F-1, 3F-2, 3G-1, 3G-2 . CyP40 disaggregates A53T α-synuclein, but not Aβ42 mature fibrils.FIG. 3A shows results of incubation of mature A53T α-synuclein fibrils with CyP40 significantly decreased Thioflavin T Fluorescence (p=0.0008).FIG. 3B shows transmission electron microscopy (TEM) images of A53T α-synuclein fibrils with or without addition of CyP40 (60,000× magnification, scale bar 400 nm) (FIG. 3C ) ThT fluorescence of Aβ42 fibrils was not significantly affected by CyP40 treatment.FIG. 3D shows TEM of mature Aβ42 fibrils showed no apparent change in morphology following CyP40 co-incubation (60,000× magnification, scale bar 400 nm).FIGS. 3E-1 and 3E-2 show NTA of tau fibrils incubated with CyP40 shows less aggregate populations in the 300-850 nm range.FIGS. 3F-1 and 3F-2 show NTA of A53T α-synuclein fibrils incubated with CyP40 shows a lack of aggregate populations in the 200-450 nm range.FIGS. 3G-1 and 3G-2 show NTA did not reveal an apparent change in size distribution of fibrils between Aβ42 control and CyP40-treated samples. -
FIGS. 4A-4F . CyP40-mediated disaggregation depends on prolyl-isomerase activity of the enzyme as shown in vitro and in an inducible cell model overexpressing P301L tau.FIG. 4A shows results of a coupled chymotrypsin assay, revealing isomerase activity in wild-type (wt) CyP40, but not mutant (mut) CyP40 as compared to the no enzyme control.FIG. 4B shows that circular dichroism did not show differences between wt CyP40 and mut CyP40 secondary structures.FIG. 4C shows ThT fluorescence significantly decreased by wt CyP40 treatment of tau fibrils (p=0.0265), but not by mut CyP40 treatment. (FIG. 4D ) Transmission electron microscopy showed straight and curved mature tau fibers 300-600 nm in length that were disintegrated by co-incubation with wt CyP40, but not mut CyP40 treatment (scale bar 400 nm, 200 nm inset).FIG. 4E shows inducible HEK cells overexpressing tau P301L (iHEK-P301L) that were induced onday 1 show increasing insoluble tau levels after 11 days of overexpression. Vector-transfected and mut CyP40-transfected cells did not affect insoluble tau levels, while wt CyP40-transfected cells showed a decrease in insoluble tau levels as depicted in line graph (FIG. 4F ). - SEQ ID NO:1 is an amino acid sequence of a human CyP40 polypeptide: mshpspqakp snpsnprvff dvdiggervg rivlelfadi vpktaenfra lctgekgigh ttgkplhfkg cpfhriikkf miqggdfsnq ngtggesiyg ekfedenfhy khdregllsm anagrntngs qffittvptp hldgkhvvfg qvikgigvar ilenvevkge kpaklcviae cgelkegddg gifpkdgsgd shpdfpedad idlkdvdkil litedlknig ntffksqnwe maikkyaevl ryvdsskavi etadraklqp ialscvlnig acklkmsnwq gaidscleal eldpsntkal yrraqgwqgl keydqaladl kkaqgiaped kaiqaellkv kqkikaqkdk ekavyakmfa
(NCBI Accession Number Q08752, version Q08752.3 GI:729274). - The present invention concerns materials and methods for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof.
- Thus, one aspect of the invention concerns a method for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, the method comprising administering an effective amount of CyP40, or a biologically-active fragment thereof, to a subject in need thereof. In some embodiments, prior to said administering, the method further comprises identifying the subject as having a neurodegenerative disease or condition associated amyloid fibril aggregation. Methods for diagnosing neurodegenerative diseases or conditions are known in the art can be utilized, such as imaging and other tests (30-32).
- Another aspect of the invention concerns a method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of CyP40, or a biologically-active fragment thereof, in vitro or in vivo.
- Another aspect of the invention concerns a composition comprising CyP40, or a biologically-active fragment thereof; and an agent effective for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation.
- In some embodiments of the methods, compositions, dosage forms, and kits of the invention, the CyP40 polypeptide is human CyP40 (SEQ ID NO:1), or a biologically active fragment or variant thereof.
- In one embodiment, a method of the invention for treating or preventing a neurodegenerative disease or a condition associated with aggregation of amyloid fibrils, comprises administering an effective amount of CyP40, or a biologically-active fragment or variant thereof, or a polynucleotide encoding the same, to a human or animal subject in need thereof. In some embodiments of the method for treating or preventing a neurodegenerative disease or condition, the disease or condition is characterized the presence of neurofibrillary aggregates of proline-containing fibrils. In one embodiment of the method for treating or preventing a neurodegenerative disease or condition, the disease or condition is characterized by the presence of neurofibrillary aggregates of protein tau and/or α-synuclein in a cell, such as a neuronal or glial cell. Diseases and conditions contemplated within the scope of the invention include, but are not limited to, Alzheimer's disease, gangliogliomas and gangliocytomas, argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, frontotemporal dementia with parkinsonism linked to chromosome17, Pick's disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease (type C), Parkinsonism-dementia complex of Guam, postencephalitic parkinsonism, prion diseases (some), progressive subcortical gliosis, and progressive supranuclear palsy. The disease or condition may be early onset or late onset. For example, in the case of Alzheimer's disease, the disease may be early onset, late onset, or familial Alzheimer's disease.
- In a specific embodiment of the method, CyP40 is administered to the human or non-human animal subject or is delivered to a target cell in the subject via a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment or variant thereof. In one embodiment, the CyP40 polypeptide is a human CyP40 (GenBank Accession No. Q08752, version Q08752.3 GI:729274). In a specific embodiment, the human CyP40 polypeptide comprises the amino acid sequence of SEQ ID NO:1, or a biologically active fragment or variant thereof. In one embodiment, a method of the invention comprises injecting (e.g., via stereotaxic injection) a polynucleotide expression construct of the invention comprising a polynucleotide encoding a CyP40 polypeptide directly into neural tissue and/or cells of a human or non-human animal subject. In a specific embodiment, the expression construct is an adeno-associated viral construct. Optionally, other biologically active agents such as drugs and therapeutics, useful in treating neurodegenerative diseases and conditions can also be administered to the human or animal. The other drugs and therapeutics can be administered to the human or animal prior to, at the same time (co-administered), or subsequent to administration of the CyP40 polypeptide or polynucleotide encoding the same. Examples of other drugs or therapeutics that can be administered include, but are not limited to, donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Akatinol), and L-dopa.
- In some embodiments, the other biologically active agent is another agent that is effective in treating or preventing a neurodegenerative disease, such as those associated with amyloid fibril aggregation. In some embodiments, the other biologically active agent is another agent having fibril disaggregation activity, such as chaperone Hsp70. In some embodiments, the other biologically active agent is a polypeptide having disaggregation activity, such as a chaperone Hsp70 polypeptide, and the other biologically active agent is coupled to a CyP40 polypeptide, or a biologically active fragment thereof, as a complex, and the polypeptide complex, or polynucleotide encoding the polypeptide complex, is administered to the subject or brought into contact with the amyloid fibrils in vitro or in vivo.
- The subject invention also concerns a method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of CyP40, or a biologically active fragment thereof, in vitro or in vivo. In some embodiments, the neurofibrillary aggregates comprise proline-containing fibrils. In some embodiments, the neurofibrillary aggregates comprise protein tau and/or α-synuclein.
- In some embodiments, a CyP40 polypeptide, or a biologically active fragment or variant thereof, or a polynucleotide encoding the same, is contacted with or provided to a target cell. The target cell can be a neuron or a glial cell. In a specific embodiment, a CyP40 polypeptide is delivered to the target cell via a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment or variant thereof. In one embodiment, the CyP40 polypeptide is a human CyP40 polypeptide. In a specific embodiment, the human CyP40 polypeptide comprises the amino acid sequence of SEQ ID NO:1, or a biologically active fragment or variant thereof. In one embodiment, a method of the invention comprises injecting (e.g., via stereotaxic injection) a polynucleotide expression construct of the invention comprising a polynucleotide encoding a CyP40 polypeptide directly into neural tissue or cells of a human or non-human animal subject. In a specific embodiment, the expression construct is an adeno-associated viral construct. An expression construct of the invention can be designed to provide for constitutive expression of a CyP40 polypeptide in a target cell or tissue. Optionally, other biologically active agents such as drugs and therapeutics useful in methods for disaggregating neurofibrillary aggregates in a target cell can also be contacted or provided to a target cell. The other biologically active agents can be provided or contacted prior to, at the same time (co-administered), or subsequent to administration of the CyP40 polypeptide or polynucleotide encoding the same. Examples of other drugs or therapeutics that can be administered include, but are not limited to, paclitaxel, a statin, lithium, inhibitors of cyclin-
dependent kinase 5, and methylthionine chloride. - The subject invention also concerns compositions comprising i) a CyP40 polypeptide, or a biologically active fragment or variant thereof, and/or ii) a polynucleotide encoding an a CyP40 polypeptide, or a biologically active fragment or variant thereof. The polynucleotide can be an expression construct that provides for expression of a CyP40 polypeptide in a target cell. In one embodiment, the CyP40 polypeptide is a human CyP40 polypeptide. In a specific embodiment, the human CyP40 polypeptide comprises the amino acid sequence of SEQ ID NO:1, or a biologically active fragment or variant thereof. Compositions of the invention can also comprise other biologically active agents such as drugs or therapeutics, examples of which include, but are not limited to, donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Akatinol), paclitaxel (Taxol), a statin, lithium, inhibitors of cyclin-
dependent kinase 5, methylthionine chloride, and L-dopa. - In some embodiments, the polypeptides and polynucleotides in the composition, and/or administered to the subject, are in isolated form.
- The polypeptides of the present invention can be formulated into pharmaceutically-acceptable salt forms. Pharmaceutically acceptable salt forms include the acid addition salts and include hydrochloric, hydrobromic, nitric, phosphoric, carbonic, sulphuric, and organic acids like acetic, propionic, benzoic, succinic, fumaric, mandelic, oxalic, citric, tartaric, maleic, and the like. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, and magnesium salts.
- Pharmaceutically acceptable salts of the polypeptides of the invention can be prepared using conventional techniques.
- The subject invention also concerns polynucleotide expression constructs that comprise a polynucleotide of the present invention comprising a nucleotide sequence encoding a CyP40 polypeptide of the present invention. In one embodiment, the CyP40 polypeptide is a human CyP40 polypeptide. In one embodiment, the polynucleotide encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:1, or a fragment or variant thereof that exhibits CyP40's disaggregation activity.
- As used herein, the term “expression construct” refers to a combination of nucleic acid sequences that provides for transcription of an operably linked nucleic acid sequence. As used herein, the term “operably linked” refers to a juxtaposition of the components described wherein the components are in a relationship that permits them to function in their intended manner. In general, operably linked components are in contiguous relation.
- Expression constructs of the invention will also generally include regulatory elements that are functional in the intended host cell in which the expression construct is to be expressed. Thus, a person of ordinary skill in the art can select regulatory elements for use in, for example, bacterial host cells, yeast host cells, plant host cells, insect host cells, mammalian host cells, and human host cells. Regulatory elements include promoters, transcription termination sequences, translation termination sequences, enhancers, and polyadenylation elements.
- An expression construct of the invention can comprise a promoter sequence operably linked to a polynucleotide sequence encoding a polypeptide of the invention. Promoters can be incorporated into a polynucleotide using standard techniques known in the art. Multiple copies of promoters or multiple promoters can be used in an expression construct of the invention. In a preferred embodiment, a promoter can be positioned about the same distance from the transcription start site as it is from the transcription start site in its natural genetic environment. Some variation in this distance is permitted without substantial decrease in promoter activity. A transcription start site is typically included in the expression construct.
- For expression in animal cells, an expression construct of the invention can comprise suitable promoters that can drive transcription of the polynucleotide sequence. If the cells are mammalian cells, then promoters such as, for example, actin promoter, metallothionein promoter, NF-kappaB promoter, EGR promoter, SRE promoter, IL-2 promoter, NFAT promoter, osteocalcin promoter, SV40 early promoter and SV40 late promoter, Lck promoter, BMP5 promoter, TRP-1 promoter, murine mammary tumor virus long terminal repeat promoter, STAT promoter, or an immunoglobulin promoter can be used in the expression construct. In one embodiment, the expression construct comprises a promoter that can drive expression of a polynucleotide of the invention in neuronal or glial cells. Promoters effective in neurons that can be used in the present invention include gamma-aminobutyric acid type A receptor β1 subunit promoter (U.S. Pat. No. 6,066,726), zebrafish HuC promoter (U.S. Published Application No. 20040093630), and cellular adhesion molecule ICAM-4 promoter (U.S. Pat. No. 5,753,502) (see also U.S. Pat. No. 6,040,172).
- Expression constructs of the invention may optionally contain a transcription termination sequence, a translation termination sequence, signal polypeptide sequence, and/or enhancer elements. Transcription termination regions can typically be obtained from the 3′ untranslated region of a eukaryotic or viral gene sequence. Transcription termination sequences can be positioned downstream of a coding sequence to provide for efficient termination. Signal polypeptides are a group of short amino terminal sequences that encode information responsible for the relocation of an operably linked polypeptide to a wide range of post-translational cellular destinations, ranging from a specific organelle compartment to sites of protein action and the extracellular environment. Targeting a polypeptide to an intended cellular and/or extracellular destination through the use of operably linked signal polypeptide sequence is contemplated for use with the polypeptides of the invention. Chemical enhancers are cis-acting elements that increase gene transcription and can also be included in the expression construct. Chemical enhancer elements are known in the art, and include, but are not limited to, the CaMV 35S enhancer element, cytomegalovirus (CMV) early promoter enhancer element, and the SV40 enhancer element. DNA sequences which direct polyadenylation of the mRNA encoded by the structural gene can also be included in the expression construct.
- Unique restriction enzyme sites can be included at the 5′ and 3′ ends of the expression construct to allow for insertion into a polynucleotide vector. As used herein, the term “vector” refers to any genetic element, including for example, plasmids, cosmids, chromosomes, phage, virus, and the like, which is capable of replication when associated with proper control elements and which can transfer polynucleotide sequences between cells. Vectors contain a nucleotide sequence that permits the vector to replicate in a selected host cell. A number of vectors are available for expression and/or cloning, and include, but are not limited to, pBR322, pUC series, M13 series, and pBLUESCRIPT vectors (Stratagene, La Jolla, Calif.). A specific vector contemplated by the present invention is an adeno-associated virus.
- Polynucleotides, vectors, and expression constructs of the subject invention can be introduced into a cell by methods known in the art. Such methods include transfection, microinjection, electroporation, lipofection, cell fusion, calcium phosphate precipitation, and by biolistic methods. In one embodiment, a polynucleotide or expression construct of the invention can be introduced in vivo via a viral vector such as adeno-associated virus (AAV), herpes simplex virus (HSV), papillomavirus, adenovirus, and Epstein-Barr virus (EBV). Attenuated or defective forms of viral vectors that can be used with the subject invention are known in the art. Typically, defective virus is not capable of infection after the virus is introduced into a cell. Polynucleotides, vectors, and expression constructs of the invention can also be introduced in vivo via lipofection (DNA transfection via liposomes prepared from synthetic cationic lipids) (Felgner et al., 1987). Synthetic cationic lipids (LIPOFECTIN, Invitrogen Corp., La Jolla, Calif.) can be used to prepare liposomes to encapsulate a polynucleotide, vector, or expression construct of the invention. A polynucleotide, vector, or expression construct of the invention can also be introduced in vivo as naked DNA using methods known in the art, such as transfection, microinjection, electroporation, calcium phosphate precipitation, and by biolistic methods.
- The present invention includes biologically active fragments and variants of CYP40 polypeptides and encoding polynucleotides. Thus, polynucleotides and polypeptides of the subject invention can also be defined in terms of more particular identity and/or similarity ranges with those sequences exemplified herein, such as SEQ ID NO:1. The sequence identity with sequences exemplified herein, such as SEQ ID NO:1, will typically be greater than 60%, preferably greater than 75%, more preferably greater than 80%, even more preferably greater than 90%, and can be greater than 95%. The identity and/or similarity of a sequence can be 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% as compared to a sequence exemplified herein, such as SEQ ID NO:1. Unless otherwise specified, as used herein percent sequence identity and/or similarity of two sequences can be determined using the algorithm of Karlin and Altschul (1990), modified as in Karlin and Altschul (1993). Such an algorithm is incorporated into the NBLAST and)(BLAST programs of Altschul et al. (1990). BLAST searches can be performed with the NBLAST program, score=100, wordlength=12, to obtain sequences with the desired percent sequence identity. To obtain gapped alignments for comparison purposes, Gapped BLAST can be used as described in Altschul et al. (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (NBLAST and)(BLAST) can be used. See NCBI/NIH website.
- The subject invention also contemplates those polynucleotide molecules (encoding polypeptides of the invention) having sequences which are sufficiently homologous with the polynucleotide sequences encoding a polypeptide of the invention so as to permit hybridization with that sequence under standard stringent conditions and standard methods (Maniatis, T. et al., 1982). As used herein, “stringent” conditions for hybridization refers to conditions wherein hybridization is typically carried out overnight at 20-25 C below the melting temperature (Tm) of the DNA hybrid in 6×SSPE, 5×Denhardt's solution, 0.1% SDS, 0.1 mg/ml denatured DNA. The melting temperature is described by the following formula (Beltz, G.A. et al., 1983):
- Tm=81.5 C+16.6 Log[Na+]+0.41(%G+C)−0.61(% formamide)−600/length of duplex in base pairs.
- Washes are typically carried out as follows:
- (1) Twice at room temperature for 15 minutes in 1×SSPE, 0.1% SDS (low stringency wash).
- (2) Once at Tm-20 C for 15 minutes in 0.2×SSPE, 0.1% SDS (moderate stringency wash).
- In some embodiments, the biologically active variant has one or both of the following characteristics: retains prolyl isomerase activity, and retains the isomerase domain. In some embodiments, the biologically active variant is a biologically active variant of human CyP40 (SEQ ID NO:1) that has one or more of the following characteristics: retains prolyl isomerase activity; retains the isomerase domain; and greater than 60%, greater than 75%, greater than 80%, greater than 90%, greater than 95% sequence identity, or greater than 98% sequence identity to SEQ ID NO:1. The structure of human CyP40 protein has been described and is incorporated herein by reference in its entirety (27, 33-34).
- The subject invention also contemplates biologically active fragments of full-length CyP40 polypeptides and polynucleotides that encode such fragments. In some embodiments, the biologically active fragment has one or both of the following characteristics: retains prolyl isomerase activity, and retains the isomerase domain. In some embodiments, the biologically active fragment is a biologically active fragment of full length human CyP40 (SEQ ID NO:1) that has one or both of the following characteristics: retains prolyl isomerase activity, and retains the isomerase domain (27, 33-34).
- As used herein, in the context of fragments and variants of CyP40, the term “biologically active” refers to CYP40's amyloid fibril disaggregation activity. Methods for determining the capacity for disaggregation activity, which may be used for assessing variant and fragment sequences, are described herein.
- As used herein, the term “biologically active agent” refers to agents such as drugs and biologics that are non-inert and have some effect on the body.
- As used herein, the terms “nucleic acid”, “polynucleotide”, and “polynucleotide sequence” refer to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally-occurring nucleotides. The polynucleotide sequences include both the DNA strand sequence that is transcribed into RNA and the RNA sequence that is translated into protein. The polynucleotide sequences include both full-length sequences as well as shorter sequences derived from the full-length sequences (e.g., biologically active fragments). It is understood that a particular polynucleotide sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell. The polynucleotide sequences falling within the scope of the subject invention further include sequences which specifically hybridize with the sequences coding for a polypeptide of the invention. The polynucleotide includes both the sense and antisense strands as either individual strands or in the duplex.
- In one embodiment, an effective amount of a polypeptide, polynucleotide, and/or composition of the present invention is administered to a subject having a neurodegenerative disorder or condition associated with amyloid fibril aggregation and who is in need of treatment thereof. The subject can be a human or other mammal, such as a dog, cat, or horse, or other animals having the disorder. Means for administering and formulating polypeptides and polynucleotides for administration to a patient are known in the art, examples of which are described herein. Polypeptides, polynucleotides, and/or compositions of the invention can be delivered to a cell either through direct contact of polypeptide or polynucleotide with the cell or via a carrier means. In one embodiment, a polypeptide or polynucleotide of the invention comprises an attached group that enhances cellular uptake of the polypeptide. In one embodiment, the polypeptide or polynucleotide is attached to an antibody that binds to a targeted cell. In another embodiment, the polypeptide or polynucleotide is encapsulated in a liposome. Polypeptides can also be delivered using a polynucleotide that encodes a subject polypeptide. Any polynucleotide having a nucleotide sequence that encodes a polypeptide of the invention is contemplated within the scope of the invention. In one embodiment, the polynucleotide is delivered to the cell where it is taken up and the polynucleotide is transcribed into RNA and the RNA is translated into the encoded polypeptide.
- Therapeutic application of the subject polypeptides and polynucleotides, and compositions containing them, can be accomplished by any suitable therapeutic method and technique presently or prospectively known to those skilled in the art. The polypeptides and polynucleotides can be administered by any suitable route known in the art including, for example, oral, intramuscular, intraspinal, intracranial, nasal, rectal, parenteral, subcutaneous, or intravenous routes of administration. Administration of the polypeptides and polynucleotides of the invention can be continuous or at distinct intervals as can be readily determined by a person skilled in the art.
- Compounds and compositions useful in the subject invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations are described in detail in a number of sources which are well known and readily available to those skilled in the art. For example, Remington's Pharmaceutical Science by E.W. Martin describes formulations which can be used in connection with the subject invention. In general, the compositions of the subject invention will be formulated such that an effective amount of the bioactive polypeptide or polynucleotide is combined with a suitable carrier in order to facilitate effective administration of the composition. The compositions used in the present methods can also be in a variety of forms. These include, for example, solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspension, suppositories, injectable and infusible solutions, and sprays. The preferred form depends on the intended mode of administration and therapeutic application. The compositions also preferably include conventional pharmaceutically acceptable carriers and diluents which are known to those skilled in the art. Examples of carriers or diluents for use with the subject polypeptides and polynucleotides include, but are not limited to, water, saline, oils including mineral oil, ethanol, dimethyl sulfoxide, gelatin, cyclodextrans, magnesium stearate, dextrose, cellulose, sugars, calcium carbonate, glycerol, alumina, starch, and equivalent carriers and diluents, or mixtures of any of these. Formulations of the polypeptide or polynucleotide of the invention can also comprise suspension agents, protectants, lubricants, buffers, preservatives, and stabilizers. To provide for the administration of such dosages for the desired therapeutic treatment, pharmaceutical compositions of the invention will advantageously comprise between about 0.1% and 45%, and especially, 1 and 15% by weight of the total of one or more of the polypeptide or polynucleotide based on the weight of the total composition including carrier or diluent.
- The compounds and molecules of the subject invention can also be administered utilizing liposome technology, slow release capsules, implantable pumps, and biodegradable containers. These delivery methods can, advantageously, provide a uniform dosage over an extended period of time.
- The subject polypeptides and polynucleotides of the invention can also be modified by the addition of chemical groups, such as PEG (polyethylene glycol). PEGylated polypeptides typically generate less of an immunogenic response and exhibit extended half-lives in vivo in comparison to polypeptides that are not PEGylated when administered in vivo. Methods for PEGylating proteins and polypeptides known in the art (see, for example, U.S. Pat. No. 4,179,337). The subject polypeptides and polynucleotides can also be modified to improve cell membrane permeability. In one embodiment, cell membrane permeability can be improved by attaching a lipophilic moiety, such as a steroid, to the polypeptide or polynucleotide. Other groups known in the art can be linked to polypeptides or polynucleotides of the present invention.
- The subject invention also concerns a packaged dosage formulation comprising in one or more packages, packets, or containers at least one polypeptide or polynucleotide and/or composition of the subject invention formulated in a pharmaceutically acceptable dosage. The package can contain discrete quantities of the dosage formulation, such as tablet, capsules, lozenge, and powders. The quantity of polypeptide or polynucleotide in a dosage formulation and that can be administered to a patient can vary from about 1 mg to about 5000 mg, or about 1 mg to about 2000 mg, or more typically about 1 mg to about 500 mg, or about 5 mg to about 250 mg, or about 10 mg to about 100 mg.
- The subject invention also concerns kits comprising in one or more containers a composition, compound, or molecule of the present invention. In one embodiment, a kit contains a polypeptide or polynucleotide of the present invention. In a specific embodiment, a kit comprises a polypeptide comprising the amino acid sequence shown in SEQ ID NO:1, or a fragment or variant of the polypeptide that exhibits CyP40 disaggregation activity. A kit of the invention can also comprise one or more compounds, biological molecules, or drugs. In one embodiment, a kit of the invention can comprise a polypeptide or polynucleotide of the invention, and optionally comprises one or more of a drug or composition used in treating a neurodegenerative disease or condition. Examples of other drugs or therapeutics include, but are not limited to, donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), memantine (Akatinol), paclitaxel (Taxol), a statin, lithium, inhibitors of cyclin-
dependent kinase 5, methylthionine chloride, and L-dopa. - Polypeptides having one or more substitutions of amino acids other than those specifically exemplified in the subject polypeptides are also contemplated within the scope of the present invention. For example, one or more non-natural amino acids can be substituted for the amino acids of a polypeptide of the invention, so long as the polypeptide having substituted amino acids retains substantially the same activity as the polypeptide in which amino acids have not been substituted. Examples of non-natural amino acids include, but are not limited to, ornithine, citrulline, hydroxyproline, homoserine, phenylglycine, taurine, iodotyrosine, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, 2-amino butyric acid, γ-amino butyric acid, δ-amino hexanoic acid, 6-amino hexanoic acid, 2-amino isobutyric acid, 3-amino propionic acid, norleucine, norvaline, sarcosine, homocitrulline, cysteic acid, τ-butylglycine, τ-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, fluoro-amino acids, designer amino acids such as β-methyl amino acids, C-methyl amino acids, N-methyl amino acids, and amino acid analogues in general. Non-natural amino acids also include amino acids having derivatized side groups. Furthermore, any of the amino acids in the protein can be of the D (dextrorotary) form or L (levorotary) form.
- Amino acids can be generally categorized in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby a polypeptide having an amino acid of one class is replaced with another amino acid of the same class fall within the scope of the subject invention so long as the polypeptide having the substitution still retains substantially the same biological activity as a polypeptide that does not have the substitution. Table 1 below provides a listing of examples of amino acids belonging to each class.
-
TABLE 1 Class of Amino Acid Examples of Amino Acids Nonpolar Ala, Val, Leu, Ile, Pro, Met, Phe, Trp Uncharged Polar Gly, Ser, Thr, Cys, Tyr, Asn, Gln Acidic Asp, Glu Basic Lys, Arg, His - Single letter amino acid abbreviations are defined in Table 2.
-
TABLE 2 Letter Symbol Amino Acid A Alanine B Asparagine or aspartic acid C Cysteine D Aspartic Acid E Glutamic Acid F Phenylalanine G Glycine H Histidine I Isoleucine K Lysine L Leucine M Methionine N Asparagine P Proline Q Glutamine R Arginine S Serine T Threonine V Valine W Tryptophan Y Tyrosine Z Glutamine or glutamic acid - The methods and compositions of the present invention can be used in the treatment of humans and non-human animals. The animals contemplated within the scope of the invention include domesticated, agricultural, or zoo- or circus-maintained animals. Domesticated animals include, for example, dogs, cats, rabbits, ferrets, guinea pigs, hamsters, pigs, monkeys or other primates, and gerbils. Agricultural animals include, for example, horses, mules, donkeys, burros, cattle, cows, pigs, sheep, and alligators. Zoo- or circus-maintained animals include, for example, lions, tigers, bears, camels, giraffes, hippopotamuses, and rhinoceroses.
- As used herein, “treat” is intended to mean administer an agent to a subject, such as a human or non-human mammal (for example, a non-human animal model), in order to prevent or delay a worsening of the effects of a condition, or to partially or fully reverse the effects of the condition, such as neurodegenerative disease or a condition associated with amyloid fibril aggregation. In some embodiments, the condition is characterized by the presence of neurofibrillary aggregates of the microtubule associated protein tau and/or alpha-synuclein.
- As used herein, “prevent” is intended to mean prophylaxis, or to reduce or minimize the chance that a subject who has an increased susceptibility for developing a condition will develop the condition, or to delay the onset of the condition, such as neurodegenerative disease or a condition associated with amyloid fibril aggregation. In some embodiments, the condition is characterized by the presence of neurofibrillary aggregates of the microtubule associated protein tau and/or alpha-synuclein.
- As used herein, “effective amount” of an agent, such as a polypeptide or a polynucleotide encoding the polypeptide, is intended to mean a sufficient amount of the agent to provide the desired effect. The exact amount required will vary, depending on the subject, species, age, and general condition of the subject, the severity of disease (or underlying genetic defect) that is being treated, the particular agent used, its mode of administration, and the like. An appropriate “effective amount” may be determined by one of ordinary skill in the art using routine experimentation.
- As used herein, “isolated polypeptide” or “purified polypeptide” is intended to mean a polypeptide (or a fragment thereof) that is substantially free from the materials with which the polypeptide is normally associated in nature. The polypeptides of the invention, or fragments thereof, can be obtained, for example, by extraction from a natural source (for example, a mammalian cell), by expression of a recombinant nucleic acid encoding the polypeptide (for example, in a cell or in a cell-free translation system), or by chemically synthesizing the polypeptide. In addition, polypeptide fragments may be obtained by any of these methods, or by cleaving full-length proteins and/or polypeptides.
- As used herein, the terms “peptide”, “polypeptide”, and “protein” are used interchangeably and intended to mean both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 370 amino acid residues, polypeptides of more than 370 amino acid residues, and full-length proteins. The peptides may occur naturally or be synthetically constructed.
- As used herein, “isolated nucleic acid molecule”, “purified nucleic acid molecule”, or “isolated polynucleotide” or “purified polynucleotide” is intended to mean DNA that is free of the genes that, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA which is incorporated into or otherwise associated with a vector, such as an autonomously replicating plasmid or virus; or incorporated into the genomic DNA of a prokaryote or eukaryote (e.g., a transgene); or which exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR, restriction endonuclease digestion, or chemical or in vitro synthesis). It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence. The term “isolated nucleic acid molecule” or “isolated polynucleotide” also refers to RNA, e.g., an mRNA molecule that is encoded by an isolated DNA molecule, or that is chemically synthesized, or that is separated or substantially free from at least some cellular components, for example, other types of RNA molecules or polypeptide molecules.
-
Embodiment 1. A method for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation, said method comprising administering an effective amount of peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof, to a human or animal subject in need thereof -
Embodiment 2. The method according toembodiment 1, wherein said method further comprises identifying a subject as one in need of treatment. -
Embodiment 3. The method according toembodiment -
Embodiment 4. The method according to any one ofembodiments 1 to 3, wherein the disease or condition is Alzheimer's disease, gangliogliomas, gangliocytomas, argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, frontotemporal dementia with parkinsonism linked to chromosome17, Pick's disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease (type C), Parkinsonism-dementia complex of Guam, postencephalitic parkinsonism, prion diseases, progressive subcortical gliosis, or progressive supranuclear palsy. -
Embodiment 5. The method according to any one ofembodiments 1 to 4, wherein the CyP40, or a biologically active fragment thereof, is administered to the subject orally, nasally, rectally, parenterally, subcutaneously, intramuscularly, intraspinal, intracranially, or intravenously. -
Embodiment 6. The method according to any one ofembodiments 1 to 5, wherein the CyP40, or a biologically fragment thereof, is administered to the subject as a polynucleotide encoding the CyP40, or the biologically active fragment thereof. -
Embodiment 7. The method according to any one ofembodiments 1 to 6, wherein the polynucleotide is provided in an expression construct. -
Embodiment 8. The method according to any one ofembodiments 1 to 7, wherein the CyP40 is a human CyP40. -
Embodiment 9. The method according toembodiment 6, wherein the polynucleotide is injected directly into neural tissue and/or cells of the subject. -
Embodiment 10. The method according toembodiment 7, wherein the expression construct comprises a promoter that provides for expression of the polynucleotide in neurons or glial cells. -
Embodiment 11. The method according toembodiment 7, wherein the expression construct is an adeno-associated viral construct. - Embodment 12. The method according to any one of
embodiments 1 to 11, wherein said method further comprises administering a biologically active agent used in treating neurodegenerative diseases and/or conditions to the subject. - Embodiment 13. The method according to embodiment 12, wherein the biologically active agent is administered prior to, or at the same time as, or subsequent to, administration of the CyP40, or the biologically active fragment thereof.
- Embodiment 14. The method according to embodiment 12 or 13, wherein the biologically active agent is one or more of donepezil, galantamine, rivastigmine, memantine, or L-dopa.
- Embodiment 15. The method according to any preceding embodiment, wherein the subject has the neurodegenerative disease or condition at the time of said administering, and the CyP40, or a biologically-active fragment thereof, is administered as therapy.
- Embodiment 16. The method according to any one of
embodiments 1 to 14, wherein the subject does not have the neurodegenerative disease or condition at the time of said administering, and the CyP40, or a biologically-active fragment thereof, is administered as prophylaxis. - Embodiment 17. A method for disaggregating neurofibrillary aggregates, comprising contacting the aggregates with an effective amount of peptidyl-prolyl isomerase cyclophilin 40 (CyP40), or a biologically-active fragment thereof, in vitro or in vivo.
- Embodiment 18. The method of embodiment 17, wherein the neurofibrillary aggregates comprise microtubule associated protein tau and/or α-synuclein.
- Embodiment 19. The method according to embodiment 17 or 18, wherein said contacting is in vivo and comprises administering the CyP40, or a biologically active fragment thereof, to a human or animal subject, and wherein the CyP40, or a biologically active fragment thereof, is administered to the subject orally, nasally, rectally, parenterally, subcutaneously, intramuscularly, intraspinal, intracranially, or intravascularly (e.g., intravenously).
-
Embodiment 20. The method according to any one of embodiments 17 to 19, wherein said contacting is in vivo and comprises administering the CyP40, or a biologically active fragment thereof, to a human or animal subject, and wherein the CyP40, or a biologically fragment thereof, is administered as a polynucleotide encoding the CyP40, or the biologically active fragment thereof. - Embodiment 21. The method according to
embodiment 20, wherein the polynucleotide is provided in an expression construct. - Embodiment 22. The method according to any one of 17 to 21, wherein the CyP40 is a human CyP40.
- Embodiment 23. The method according to
embodiment 20 or 21, wherein the polynucleotide is injected directly into neural tissue and/or cells of the subject. - Embodiment 24. The method according to embodiment 23, wherein the expression construct comprises a promoter that provides for expression of the polynucleotide in neurons or glial cells.
- Embodiment 25. The method according to embodiment 21, wherein the expression construct is an adeno-associated viral construct.
- Embodiment 26. The method according to any one of embodiments 17 to 25, wherein said method further comprises administering a biologically active agent used in treating neurodegenerative diseases and/or conditions to the subject.
- Embodiment 27. The method according to embodiment 26, wherein the biologically active agent is administered prior to, or at the same time as, or subsequent to, administration of the CyP40, or the biologically active fragment thereof.
- Embodiment 28. The method according to embodiment 26, wherein the biologically active agent is one or more of donepezil, galantamine, rivastigmine, memantine, or L-dopa.
- Embodiment 29. A composition comprising a peptidyl-prolyl isomerase cyclophilin 40 (CyP40) polypeptide, or a biologically active fragment thereof or a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment thereof.
-
Embodiment 30. The composition of embodiment 29, wherein said composition comprises a physiologically acceptable buffer, carrier, and/or diluent. - Embodiment 31. The composition of
embodiment 29 or 30, further comprising an agent effective for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation. - Embodiment 32. The composition of any one of embodiment 29 to 31, further comprising an agent having amyloid fibril disaggregation activity in vitro or in vivo.
- Embodiment 33. A packaged dosage formulation comprising at least one of i) a CyP40 polypeptide, or a biologically active fragment thereof and/or ii) a polynucleotide encoding a CyP40 polypeptide, or a biologically active fragment thereof; in a pharmaceutically acceptable dosage in one or more packages, packets, or containers.
- Embodiment 34. The packaged dosage formulation according to embodiment 33, wherein said CyP40 polypeptide or said polynucleotide is provided as a tablet, capsule, lozenge, or powder.
- Embodiment 35. The packaged dosage formulation according to embodiment 33, wherein said polynucleotide is provided in an expression construct.
- Embodiment 36. The packaged dosage formulation according to embodiment 35, wherein said expression construct comprises a promoter that provides for expression of said polynucleotide in neurons or glial cells.
- Embodiment 37. The packaged dosage formulation according to any one of embodiments 33 to 36, wherein said one or more packages, packets, or containers further comprise a biologically active agent useful in treating neurodegenerative disease or condition.
- Embodiment 38. The packaged dosage formulation according to any one of embodiments 33 to 37, wherein said one or more packages, packets, or contains further comprise a biologically active agent useful for disagreggating neurofibrillary aggregates.
- Embodiment 39. A kit comprising in one or more containers a CyP40 polypeptide, or a biologically active fragment thereof, and/or a polynucleotide encoding said CyP40 polypeptide, or said biologically active fragment thereof.
-
Embodiment 40. The kit according to embodiment 39, wherein said polynucleotide is provided in an expression construct. - Embodiment 41. The kit according to
embodiment 40, wherein said expression construct comprises a promoter that provides for expression of said polynucleotide in neurons or glial cells. - Embodiment 42. The kit according to embodiment 39, wherein said one or more containers further comprise a biologically active agent useful in treating neurodegenerative disease or condition.
- Embodiment 43. The kit according to embodiment 39, wherein said one or more containers further comprises a biologically active agent useful for disagreggating neurofibrillary aggregates.
- Embodiment 44. The method, composition, packaged dosage formulation, or kit according to any one of
embodiments 1 to 43, wherein the CyP40 is human CyP40. - Embodiment 45. The method, composition, packaged dosage formulation, or kit according to any one of
embodiments 1 to 43, wherein the CyP40 comprises the amino acid sequence of SEQ ID NO:1. - Protein Purification. Recombinant human P301L tau, CyP40, CyP40 H141E, CyPA, FKBP51, and FKBP52 were cloned into Pet28 plasmids, and then transformed into competent E. coli BL21 cells and plated on kanamycin-agar plates and incubated at 37° C. overnight (˜16 hours). A single colony was used to inoculate a 10 mL starter culture of LB broth supplemented with kanamycin. After 8-12 hours, starter cultures were used to inoculate 1 L of LB-kanamycin broth and cultures were grown to an OD600 of 0.8 (˜3 hrs). At this point, cultures were induced with 1 mM (final concentration) IPTG and grown a further 3 hours. Pellets were spun down at 3500×g for 30 minutes and supernatant was discarded by aspiration. Pellets were then resuspended in Nickel chromatography running buffer (20 mM Tris-HC1 pH 8.0, 500 mM NaCl, 10 mM Imidazole) and frozen for up to 3 months at −80° C.
- Pellets were then thawed on ice and subsequently lysed by sonication and spun at 50,000×g for 1 hour. After filtration of the supernatant with a 0.02 μm filter, a standard gravity nickel column using Ni-NTA resin (Fisher #PI88222) was performed. TEV protease was then added to the elution fraction, placed into a 3,000 MW cutoff dialysis bag and into TEV buffer overnight at 4° C. The solution was then dialyzed back into nickel chromatography running buffer and a 2nd nickel purification column was ran. We then performed size exclusion chromatography using a HiLoad 16/600 Superdex 200pg column and fractions were pooled and concentrated. Proteins were then dialyzed into appropriate buffer (PBS or Sodium Acetate). Proteins were estimated to be >95% pure by coomassie staining.
- Amyloid Beta protein fragment 42 was purchased from Sigma Aldrich (107761-42-2), and mature α-synuclein fibrils were a generous gift from Dr. Vladimir Uversky at USF.
- Fibril formation. 50 μM recombinant human tau P301L was incubated in the presence of 12.5 μM low molecular weight heparin (4:1 molar ratio) at 37° C. in 100 mM Sodium Acetate pH 7.0 buffer without agitation for 7 days. Thioflavin T fluorescence was recorded throughout fibrillation in order to confirm plateau of fluorescence. Aβ42 fibrils were formed by suspending the lyophilized protein in minimal 60 mM NaOH and then diluting to a final concentration of 50 μM in PBS buffer. The solution was then shaken at 700 rpm at 37° C. for 5 days.
- Thioflavin T Fluorescence Assay. 7.5 μM pre-formed fibril was incubated with 7.5 μM CyP40 protein (wt or mut where indicated) in 100 μM Sodium Acetate pH 7.0 buffer (or PBS for α-synuclein and Aβ42) in a 96-well black clear-bottom plate (Fisher #07-200-525). Final volume before ThT addition was 100 μL per sample. At set time points (0, 1, 3 hours), 7.5 μM Thioflavin T (final concentration) was added and fluorescence read at 440 nm excitation and 482 nm emission in a BioTek Synergy H1 plate reader.
- Transmission Electron Microscopy. 10 μL of protein samples were adsorbed onto 300 mesh square mesh copper grids (EMS300-Cu) for 30 seconds. Grids were then washed twice with 10 μL of deionized water and excess water wicked with filter paper. Grids were negatively stained with 4% uranyl acetate for 30 seconds and dried overnight. Grids were viewed using a JEOL 1400 Digital Transmission Electron Microscope and images were captured with a Gatan Orius wide-field camera. Fields shown are representative.
- Nanoparticle tracking analysis. At the end of experiments, samples were diluted 10,000 fold into 1 mL of deionized filtered water (0.02 μm). Approximately 300 μL sample was loaded onto the Malvern Nanosight LM10 equipped with a 633 nm red laser. Protein particle data was captured with a Marlin CCD camera in duplicate. Between samples, 500 μL of water was passed through the imaging chamber to clear previous sample. Graphs were generated by Nanosight software.
- Circular dichroism (CD) spectroscopy. Far-UV CD measurements were taken using a JASCO J-815 spectropolarimeter. Wt CyP40 and mut CyP40 were dialyzed into 10 mM sodium phosphate buffer, pH 7.5. Proteins were loaded into a 1 mm quartz cuvette and readings were taken at 25° C. Each spectrum is an average of 3 scans from 190-260 nm at 50 nm/min. Buffer spectral curves were subtracted for each protein.
- Chymotrypsin-coupled assay. PPIase activity was measured by a chymotrypsin-coupled assay using a synthetic peptide succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma) as previously described [28] with some modifications. Briefly, the reactions were set up in precooled 1 ml reaction buffer (50 mM Tris-HC1, pH 7.5, 150 mM NaCl, 10 mM CaCl2) by adding 5
μl 1 mM peptide, 1 μl chymotrypsin (1 mg/ml, Sigma), and 0.5 μM purified protein. The absorbance was measured every 20 seconds for 10 min at 410 nm in a Genesys 10S UV-Vis spectrophotometer (Thermo) at 4° C. - iHEK-P301L and sarkosyl soluble analysis. Tetracycline inducible HEK293 cell line (iHEK) was generated by the insertion of human P301L tau 4R0N DNA into a
pCDNA 4/TO plasmid vector (Invitrogen). The tau/TO plasmid construct was transfected into the T-REx™ HEK cell line (Invitrogen) which stably express the tetracycline repressor protein. After zeocin selection (200 μg/ml), the colonies were picked up and the expression of Tau was detected by Western blot with and without tetracycline (1 μg/ml). - To investigate the effect of CyP40 on the level of aggregated, insoluble tau, tau expression was induced for 9 days and then transfected with PCMV6-CyP40 (wildtype and H141E mutants) plasmids using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. 48 h after transfection, the sarkosyl insoluble fraction of Tau was prepared as previously described [21].
- Mouse studies and tissue processing. rTg4510 Mice were injected at 6-months old (N=9 for CyP40, N=8 for GFP), and harvested at 8-months. Mice were perfused using 0.9% saline solution after which brains were removed rapidly. Brains were fixed in 4% paraformaldehyde overnight. Sucrose gradients up to 30% were used and then tissue was sectioned with a sliding microtome to 25 μm thickness.
- Viral injection. Using stereotaxic equipment, mice were injected bilaterally into the hippocampus at X=±3.6 Y=−3.5 Z=±2.68. Each injection delivered 2 μL of adeno-associated viral particles serotype 9 tagged with either green fluorescent protein (GFP) or CyP40.
- Immunohistochemistry and immunofluorescence. Tissue was stained free floating as previously described [29].Tissue sections were incubated in PBS supplemented with 10% MeOH and 3% H2O2 to block endogenous peroxidases. Following PBS washes, tissue was permeabilized by 0.2% Triton-X-100 with 1.83% lysine and 4% serum in PBS for 30 minutes. Tissue was then incubated at room temperature overnight in primary antibody. The following primary antibodies were used, anti-CyP40 (1:2000), T22 (1:700), and anti-H150 tau (1:30000). Following three PBS washes, biotinylated goat anti-rabbit (Southern Biotech) secondary (1:10000) was added for 2 hours. Prior to peroxidase development, an ABC kit (Vectastain) was used to increase visibility. Following PBS washes, tissue was incubated with 0.05% diaminobenzidine plus 0.5% nickel and developed with 0.03% H2O2. Tissue sections were then mounted and allowed to dry overnight before dehydration in alcohol gradients. Slides were cleared by Histoclear then coverslipped with DPX.
- Sections stained for stereology were blocked and permeabilized as described above and incubated overnight with biotinylated NeuN (1:3000) at room temperature. Following PBS washes, ABC conjugation, and peroxidase development tissue was mounted on glass slides and dried overnight. These sections were then counter-stained with cresyl violet (nissl) by incubating with 0.05% cresyl violet briefly and then quickly destaining with 0.3% acetic acid in water prior to dehydration.
- For Gallyas silver staining, tissue slices were mounted on glass slides and dried overnight. These slides were then incubated in a 0.003% potassium permanganate solution for 10 min. After rinsing with water the sections were incubated from 1-2 min in a 2.0% oxalic acid solution then rinsed thoroughly in water. Slides were then incubated in a 5.0% sodium metaperiodate solution for 5 min and again rinsed in water. Slides were then treated with an alkaline silver iodide solution (1 M sodium hydroxide, 0.6 M potassium iodide, 0.053% silver nitrate) for 1 min, then rinsed three times with a 0.5% acetic acid solution. Staining was developed by combining solutions A (5% sodium carbonate), B (0.024 M ammonium nitrate, 0.012 M silver nitrate, 0.003 M tungstosilicic acid), and C (0.024 M ammonium nitrate, 0.012 M silver nitrate, 0.003 M tungstosilicic acid, 0.25% formaldehyde) in a 2:1:1 ratio, adding B and C to solution A and incubating for 10-30 min. The slides were then rinsed three times in 0.5% acetic acid, then water. The slides were then incubated in gold tone for 3-4 min and again rinsed in water, then a 1% sodium thiosulphate solution for 5 min and a final rinse in water before they were dehydrated and coverslipped using DPX.
- Tissue imaging and quantification. A slide scanning microscope (Zeiss) was used to image all tissue. Bright field analysis was performed using Zeiss Neuroquant IAE analysis software. This program was used to outline regions of interest from the entire slide. Then, thresholds were set manually until only positive cells, as determined by the analyzer, were selected with as little non-specific areas selected as possible. Using the batch process option, the Area Ratio of positive cells within the regions of interest was automatically calculated for each stained group.
- Statistical Analysis. Analyses were performed using GraphPad Prism version 5.02. Group differences were analyzed with a two-tailed student's t-test. If P<0.05, significance is indicated by a single asterisk (*). If p<0.01 significance is marked by two asterisks (**). If p<0.001, significance is shown with three asterisks (***). Error bars represent standard error of the mean (SEM).
- All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
- Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
- For many proteins, amyloidogenesis is significantly affected by structurally flexible proline residues (9,10). Because β-turns are often associated with proline residues (11), the inventors speculated that enzymes capable of twisting these prolines could unravel amyloid structures. The family of cis/trans peptidyl prolyl isomerases (PPIases) is diverse (12), and perhaps most importantly does not require the use of ATP to isomerize proline residues (13). While prolyl isomerization has been implicated in the formation and prevention of protein aggregation (14,15), a role for PPIases in amyloid disaggregation has never been described. Therefore, the inventors hypothesized that discrete PPIases may be able to disaggregate mature amyloid fibrils in a proline-dependent and energy-independent manner (
FIG. 1A ). - To test this hypothesis, a screen was performed using several well-studied proteins within the PPIase superfamily, including CyPA and the Hsp90 co-chaperones, CyP40, FKBP51, and FKBP52. Individual PPIases were incubated with pre-fibrillized recombinant P301L tau for a period of 3 hours, and Thioflavin T (ThT) fluorescence was measured periodically (
FIGS. 1B and 1C ). Only CyP40 decreased ThT fluorescence, indicating a reduction in β-sheet secondary structure. Transmission electron microscopy (TEM) of these samples revealed that tau incubated with Cyp40 lacked fibrillar structure compared to control (FIG. 1D ). These data indicate that CyP40 is capable of disaggregating amyloid fibrils in vitro. - The disaggregase capacity of CyP40 was then evaluated in a mouse model overexpressing P301L tau to determine if the in vitro disaggregase activity of the PPIase had physiological relevance. Hippocampi of rTg4510 mice were injected at 6 months of age with AAV9-GFP or AAV9-CyP40 and harvested at 8 months for histological analysis (
FIG. 2A ). These ages were chosen so that the disaggregation activity of CyP40 on preformed, mature tau fibrils could be investigated. However, these time points came at the cost of not being able to discern meaningful differences in behavior given the severe hippocampal volume loss observed in these mice by 6-8 months (16-18). CyP40 overexpression significantly decreased relative insoluble tau levels by western blot (FIGS. 2B and 2C ), to a level similar to that of a 1-3 month old rTg4510 mouse [19]. - CyP40 significantly reduced the levels of total tau (
FIGS. 2D and 2E ) and even Gallyas silver-positive tau tangles (FIGS. 2F and 2G ), hallmarks of tau amyloidosis in human disease. Interestingly, the levels of oligomeric tau, as indicated by T22 immunoreactivity, were also reduced by CyP40 (FIGS. 2H and 2I ). This is important because oligomers are known to increase tau neurotoxicity (20-23), perhaps explaining the significantly increased neuronal count of CyP40-injected mice as shown by unbiased stereology (FIGS. 2J and 2K ). Collectively, these data indicate that hippocampal CyP40 overexpression reverses tau aggregation, tau oligomer formation and neuronal loss in vivo, even when administered at an age when tau pathology and hippocampal atrophy are quite advanced. - ThT fluorescence and TEM were then used to examine the effects of CyP40 on disaggregation of pre-formed aggregates of other amyloidogenic substrates, including A53T α-synuclein and the β-amyloid 1-42 peptide (Aβ42), pathological hallmarks of Parkinson's disease (PD) and Alzheimer's disease (AD), respectively. While α-synuclein contains proline residues similar to tau, Aβ42 does not, permitting insight into the proline dependence of this mechanism.
- Similar to tau, CyP40 decreased ThT fluorescence when incubated with α-synuclein fibrils compared to control (
FIG. 3A ) and TEM corroborated these results (FIG. 3B ). Conversely, CyP40 was unable to disaggregate Aβ42 by either ThT or TEM, hinting at a mechanism involving the PPIase activity and requirement for substrate proline residues (FIGS. 3C and 3D ). We then introduced a Nanoparticle Tracking Analysis (NTA) system to analyze the oligomeric profile of each of these proteins. While mature P301L tau fibrils displayed a large abundance of aggregates up to 850 nm, CyP40 co-incubated samples showed a paucity of aggregates greater than 150 nm (FIGS. 3E-1 and 3E-2). Similarly, mature A53T α-synuclein showed abundant aggregates in the 200-400 nm range, while CyP40-treated samples had greatly diminished populations in this size range (FIGS. 3F-1 and 3F-2 ). NTA confirmed the inability of CyP40 to disaggregate mature Aβ42 fibrils, as large similarly-sized aggregate particles were seen in both control and CyP40-treated samples (FIGS. 3G-1 and 3G-2 ). These data suggest that CyP40 disaggregase activity is dependent on its prolyl isomerization activity as a means of controlling substrate specificity. - To further explore this mechanism, a mutant of CyP40 lacking PPIase activity was constructed. Mutating histidine 141 to glutamate (H141E) ablated PPIase activity as shown by a chymotrypsin-coupled assay (
FIG. 4A ). Importantly, the mutation did not significantly alter secondary structure of the protein as evidenced by circular dichroism (FIG. 4B ). Wildtype (wt) and mutant (mut) CyP40 were incubated with mature P301L tau amyloid fibrils, and ThT fluorescence was recorded. Although wt CyP40 produced a significant reduction in fluorescence, mut CyP40 was incapable of disaggregating these fibrils (FIG. 4C ). Subsequent TEM analysis indicated the presence of intact mature fibrils in both the control and mut CyP40 samples, while wt CyP40 disintegrated the fibrils (FIG. 4D ). These findings also rule out the possibility that the effect of CyP40 was the result of a technical artifact brought on by recombinant protein administration facilitating the interaction properties of aggregates with polymers as previously described [24]. - To confirm the dependence of CyP40 disaggregation on its prolyl isomerase activity, an inducible cell model overexpressing P301L tau was derived (iHEK). In this model, tau overexpression is induced by tetracycline, and high molecular weight tau, indicative of aggregated, insoluble material, is evident by
day 9 and reaches a maximum intensity at 11 days post-induction as demonstrated by SDS-PAGE (FIGS. 4E and 4F ). Wt CyP40, mut CyP40, or empty vector were transfected 9 days following tetracycline administration, and sarkosyl insoluble and soluble tau fractions were analyzed. Consistent with the in vitro data, wt CyP40 was capable of reducing insoluble tau levels after 2 days of expression while the isomerase-null mutant and empty vector had little effect (FIGS. 4E and 4F ). Collectively, these data indicate that the PPIase activity of CyP40 is necessary for its disaggregation capacity. - Overall, these findings suggest that human CyP40 has a unique capacity to twist key proline residues within the structures of some amyloidogenic proteins [25,26], effectively leading to their disassembly and rendering them less neurotoxic (
FIG. 1A ). No other PPIase tested had disaggregation activity, possibly due to a unique amino acid expansion in a loop within the isomerase domain of CyP40. If responsible for its disaggregase capacity, this unique expansion could be selectively targeted without disrupting other PPIases, providing a novel mechanism to therapeutically disrupt intractable aggregates. Furthermore, cyclophilins are known to have diverse surface charges, and the unique mixed charge character of CyP40 may facilitate binding with amyloid substrates [27]. Additionally, knowing that an ATP-dependent Hsp70 disaggregase complex exists raises the possibility of an Hsp90/CyP40 disaggregase machine. Because CyP40 contains a TPR domain, it interacts with Hsp90 and this ATP-driven complex may influence disaggregation rate and substrate specificity. These machinery could be critical to the understanding of protein aggregate biology. Moreover, strategies aimed at enhancing disaggregase activity could potentially delay or even reverse pathological advance in several diseases. - It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.
- 1. P. Jaru-Ampornpan et al., Mechanism of an ATP-independent protein disaggregase: II. distinct molecular interactions drive multiple steps during aggregate disassembly. The Journal of biological chemistry 288, 13431-13445 (2013).
- 2. L. Goldschmidt, P. K. Teng, R. Riek, D. Eisenberg, Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proceedings of the National Academy of Sciences of the United States of America 107, 3487-3492 (2010).
- 3. D. Eisenberg, M. Jucker, The amyloid state of proteins in human diseases. Cell 148, 1188-1203 (2012).
- 4. H. Braak, E. Braak, Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica 82, 239-259 (1991).
- 5. X. Gao et al., Human Hsp70 Disaggregase Reverses Parkinson's-Linked alpha-Synuclein Amyloid Fibrils. Molecular cell 59, 781-793 (2015).
- 6. M. E. Jackrel et al., Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156, 170-182 (2014).
- 7. M. E. Jackrel, J. Shorter, Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Disease models &
mechanisms 7, 1175-1184 (2014). - 8. N. B. Nillegoda et al., Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 524, 247-251 (2015).
- 9. T. Chiba et al., Amyloid fibril formation in the context of full-length protein: effects of proline mutations on the amyloid fibril formation of beta2-microglobulin. The Journal of biological chemistry 278, 47016-47024 (2003).
- 10. A. Abedini, D. P. Raleigh, Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP? Journal of molecular biology 355, 274-281 (2006).
- 11. V. Y. Torbeev, D. Hilvert, Both the cis-trans equilibrium and isomerization dynamics of a single proline amide modulate β2-microglobulin amyloid assembly. Proceedings of the National Academy of Sciences of the United States of America 110, 20051-20056 (2013).
- 12. L. J. Blair, J. D. Baker, J. J. Sabbagh, C. A. Dickey, The emerging role of peptidyl-prolyl isomerase chaperones in tau. Journal of neurochemistry 133, 1-13 (2015).
- 13. H. Hodak et al., The peptidyl-prolyl isomerase and chaperone Par27 of Bordetella pertussis as the prototype for a new group of parvulins. Journal of molecular biology 376, 414-426 (2008).
- 14. J. Giustiniani et al., Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America 111, 4584-4589 (2014).
- 15. L. J. Blair et al., Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. The Journal of clinical investigation 123, 4158-4169 (2013).
- 16. J. F. Abisambra et al., Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. The Journal of neuroscience : the official journal of the Society for
Neuroscience 30, 15374-15382 (2010). - 17. K. Santacruz et al., Tau suppression in a neurodegenerative mouse model improves memory function. Science (New York, N.Y.) 309, 476-481 (2005).
- 18. T. L. Spires et al., Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. The American journal of pathology 168, 1598-1607 (2006).
- 19. C. Dickey et al., Aging Analysis Reveals Slowed Tau Turnover and Enhanced Stress Response in a Mouse Model of Tauopathy. The American journal of pathology 174, 228-238 (2009).
- 20. J. C. O′Leary, 3rd et al., Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.
Molecular neurodegeneration 5, 45 (2010). - 21. M. Ramsden et al., Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). The Journal of neuroscience: the official journal of the Society for Neuroscience 25, 10637-10647 (2005).
- 22. M. Usenovic et al., Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. The Journal of neuroscience : the official journal of the Society for Neuroscience 35, 14234-14250 (2015).
- 23. S. M. Ward, D. S. Himmelstein, J. K. Lancia, L. I. Binder, Tau oligomers and tau toxicity in neurodegenerative disease.
Biochemical Society transactions 40, 667-671 (2012). - 24. A. N. Murray, F. L. Palhano, J. Bieschke, J. W. Kelly, Surface adsorption considerations when working with amyloid fibrils in multiwell plates and Eppendorf tubes. Protein science : a publication of the Protein Society 22, 1531-1541 (2013).
- 25. A. Morimoto et al., Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement. The Journal of biological chemistry 279, 52781-52788 (2004).
- 26. A. Morimoto et al., Aggregation and neurotoxicity of mutant amyloid beta (A beta) peptides with proline replacement: importance of turn formation at positions 22 and 23. Biochemical and biophysical research communications 295, 306-311 (2002).
- 27. T. L. Davis et al., Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases.
PLoS biology 8, e1000439 (2010). - 28. U. K. Jinwal et al., The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. The Journal of neuroscience: the official journal of the Society for
Neuroscience 30, 591-599 (2010). - 29. M. N. Gordon, W. A. Schreier, X. Ou, L. A. Holcomb, D. G. Morgan, Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. The Journal of comparative neurology 388, 106-119 (1997).
- 30. M. Gomez-Rio, Caballero MM, Górriz Sáez JM, Mínguez-Castellanos A. Diagnosis of Neurodegenerative diseases: The clinical approach. Curr Alzheimer Res., 13(5): 469-474 (2016).
- 31 Juha Koikkalainen et al. Differential diagnosis of neurodegenerative diseases using structural MM data. Neuroimage Clin. 11:435-439 (2016).
- 32. A. John Stoessi. Neuroimaging in the early diagnosis of neurodegenerative disease. Translational Neurodegeneration 1(1):5 (2012).
- 33. Bryan K. Ward et al. A Structure-based Mutational Analysis of
Cyclophilin 40 Identifies Key Residues in the Core Tetratricopeptide Repeat Domain That Mediate Binding to Hsp90. The Journal of Biological Chemistry. 277(43):40799-40809 (2002). - 34. Elizabeth A. Blackburn et al. Cyclophilin40 isomerase activity is regulated by a temperature-dependent allosteric interaction with Hsp90. Biosci Rep. Oct; 35(5): e00258 (2015).
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/095,270 US20190134167A1 (en) | 2016-04-29 | 2017-04-28 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662329317P | 2016-04-29 | 2016-04-29 | |
PCT/US2017/030140 WO2017190016A1 (en) | 2016-04-29 | 2017-04-28 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
US16/095,270 US20190134167A1 (en) | 2016-04-29 | 2017-04-28 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/030140 A-371-Of-International WO2017190016A1 (en) | 2016-04-29 | 2017-04-28 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/389,169 Division US20210361753A1 (en) | 2016-04-29 | 2021-07-29 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190134167A1 true US20190134167A1 (en) | 2019-05-09 |
Family
ID=60160100
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/095,270 Abandoned US20190134167A1 (en) | 2016-04-29 | 2017-04-28 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
US17/389,169 Pending US20210361753A1 (en) | 2016-04-29 | 2021-07-29 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/389,169 Pending US20210361753A1 (en) | 2016-04-29 | 2021-07-29 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases |
Country Status (2)
Country | Link |
---|---|
US (2) | US20190134167A1 (en) |
WO (1) | WO2017190016A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE298243T1 (en) * | 1999-09-10 | 2005-07-15 | Max Planck Gesellschaft | ANT-1 AS A THERAPEUTIC TARGET MOLECULE |
DE10327937A1 (en) * | 2002-06-21 | 2004-01-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of cyclophilin D or creatine kinase for inhibiting apoptosis, useful for treating e.g. cardiac infarct and in drug screening, also use of their inhibitors for treating tumors |
US7485706B2 (en) * | 2003-07-30 | 2009-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Neurodegenerative protein aggregation inhibition methods and compounds |
GB0410101D0 (en) * | 2004-05-06 | 2004-06-09 | Leuven K U Res & Dev | Parkinson's disease |
US20100291074A1 (en) * | 2007-07-27 | 2010-11-18 | Columbia University In The City Of New York | Cyclophilin d-amyloid beta interaction potentiates mitochondrial dysfunction in a transgenic mouse model of alzheimer's disease |
-
2017
- 2017-04-28 US US16/095,270 patent/US20190134167A1/en not_active Abandoned
- 2017-04-28 WO PCT/US2017/030140 patent/WO2017190016A1/en active Application Filing
-
2021
- 2021-07-29 US US17/389,169 patent/US20210361753A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210361753A1 (en) | 2021-11-25 |
WO2017190016A1 (en) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7011467B2 (en) | Compositions and Methods for Degradation of Misfolded Proteins | |
US10337027B2 (en) | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to Friedreich ataxia | |
KR102554448B1 (en) | Structure-Based Peptide Inhibitors of Alpha-Synuclein Aggregation | |
US7632816B2 (en) | Treatment of Alzheimer amyloid deposition | |
US20130209549A1 (en) | Materials and methods for treating neurodegenerative diseases | |
HUE028500T2 (en) | Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease | |
JP4242128B2 (en) | Screening method for cerebral amyloidosis preventive and therapeutic drug | |
US20210361753A1 (en) | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | |
CN110325547B (en) | Novel amyloid beta oligomer specific binding molecules | |
AU2001264247B2 (en) | GASC1 gene | |
US7998684B2 (en) | Screening method for an agent for treatment of neurodegenerative disease | |
US10286038B2 (en) | Lysosome membrane protein 2 (LIMP-2) based peptides and related uses | |
JP2010518821A (en) | Secreted protein Ccdc80 that controls adipocyte differentiation | |
WO2010037143A1 (en) | Vectors and methods of treating brain seizures | |
JP2009506026A (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF β AMYLOID IN THE BRAIN CONTAINING GCPII (GLUTAMATE CARBOXYPEPTIDASE-II) AS ACTIVE INGREDIENT AND COMPOSITION FOR SCREENING THERAPEUTIC AGENT AND SCREENING METHOD USING THE SA | |
WO2017069182A1 (en) | Dna vaccine against amyloid-β and tau | |
JP2002507413A (en) | Members of the cytokine family, 2-21 | |
CN117940135A (en) | Compositions and methods for treating and preventing misfolded proteins | |
EP4299588A2 (en) | Treatment methods for eye disorders | |
EP4380580A2 (en) | Compositions and methods for treatment and prevention of misfolded proteins | |
US20210169980A1 (en) | Autophagy inhibitors | |
KR20240083171A (en) | Compositions and methods for treating and preventing misfolded proteins | |
WO2023115194A1 (en) | Nucleic acid constructs encoding a cell penetrating peptide, signal sequence and transcription factor eb and uses thereof | |
JP2002520291A (en) | Therapeutic use of uncoupling protein HHFCW60 | |
KR20240005950A (en) | vector system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF SOUTH FLORIDA;REEL/FRAME:047967/0949 Effective date: 20181212 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: UNIVERSITY OF SOUTH FLORIDA, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAKER, JEREMY DUSTIN;REEL/FRAME:049208/0404 Effective date: 20181120 Owner name: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DICKEY, ADRIA;REEL/FRAME:049209/0022 Effective date: 20181120 Owner name: UNIVERSITY OF SOUTH FLORIDA, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DICKEY, ADRIA;REEL/FRAME:049209/0022 Effective date: 20181120 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |